<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1306210779
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VIAGACIN
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MOXIFLOXACIN HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        41.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; V" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – V
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Viagacin contains the active substance Viagacin, which belongs to a group of antibiotics called fluoroquinolones. Viagacin works by killing bacteria that cause infections.</p><p>Viagacin is used in patients aged 18 years and above for treating the following bacterial infections when caused by bacteria against which Viagacin is&nbsp; active.&nbsp; Viagacin&nbsp; should&nbsp; only&nbsp; be&nbsp; used&nbsp; to&nbsp; treat these infections when usual antibiotics cannot be used or have not worked.</p><p>&nbsp;</p><p>Infection of the sinuses, sudden worsening of long term inflammation of the airways or infection of the lungs (pneumonia) acquired outside the hospital (except severe cases).</p><p>&nbsp;</p><p>&nbsp;</p><p>Mild to moderate infections of the female upper genital tract (pelvic inflammatory disease), including infections of the fallopian tubes and infections of the uterus mucous membrane.</p><p>&nbsp;</p><p>Viagacin tablets are not sufficient on their own for treating this kind of infection.&nbsp; Therefore, another antibiotic in addition to Viagacin tablets should be prescribed by your doctor for the treatment of infections of the female upper genital tract (see section 2. What you need to know before you take Viagacin, Warnings and precautions, Talk to your doctor before taking Viagacin).</p><p>&nbsp;</p><p>If the following bacterial infections have shown improvement during initial treatment with&nbsp; Viagacin solution for infusion, Viagacin tablets may also be prescribed by&nbsp; your&nbsp; doctor&nbsp; to&nbsp; complete the course of therapy:</p><p>Infection of the lungs (pneumonia) acquired outside the hospital, infections of the skin and soft tissue. Viagacin tablets should not be used to initiate therapy for any type of infections of the skin and soft tissue or in severe infections of the lungs.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Contact your doctor if you are not sure if you belong to a patient group described below.</p><p>&nbsp;</p><p>Do not take Viagacin</p><p>-&nbsp; If you are allergic to the active substance Viagacin, any other quinolone antibiotics or any of the other ingredients of this medicine (listed in section 6.).</p><p>-&nbsp; If you are pregnant or are breast feeding.</p><p>-&nbsp; If you are under 18 years of age.</p><p>-&nbsp; If you have previously had problems with your tendons related to treatment with quinolone antibiotics (see section Warnings and Precautions &hellip; and section 4. Possible side effects).</p><p>-&nbsp; If you were born with or have</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; any condition with abnormal heart rhythm (seen on ECG, electrical recording of the heart)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; a salt imbalance in the blood (especially&nbsp; low levels&nbsp; of potassium&nbsp; or&nbsp; magnesium in the blood)</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a very slow heart rhythm (called &lsquo;bradycardia&rsquo;)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a weak heart (heart failure)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a history of abnormal heart rhythms or</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking other medicines that result in abnormal ECG changes (see section <strong>Other medicines&nbsp; and&nbsp; Viagacin</strong>). This is because Viagacin can cause changes on the ECG, that&nbsp;&nbsp; is a prolongation of the QT-interval, i.e., delayed conduction of electrical signals.</p><p>-&nbsp; If you have a severe liver disease or increased liver enzymes (transaminases) higher than 5 times the upper normal limit.</p><p>Warnings and precautions</p><p><strong>&nbsp;</strong></p><p><strong>Talk to your doctor before taking Viagacin</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Viagacin can <strong>change your heart&rsquo;s ECG</strong>, especially if you are female, or if you are elderly.&nbsp; If you are currently taking any medicine that decreases your blood potassium levels, consult your doctor before taking Viagacin (see also sections</p><p>Do not take and Other medicines and Viagacin).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from <strong>epilepsy </strong>or a condition which makes you likely to have <strong>convulsions</strong></p><p>talk to your doctor before taking Viagacin.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have or have ever had any <strong>mental health problems</strong>, consult your doctor before taking Viagacin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from <strong>myasthenia gravis </strong>(abnormal muscle fatigue leading to weakness and in serious cases paralysis), taking Viagacin may worsen the symptoms of your disease. If you think you are affected consult your doctor immediately.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have been diagnosed with an <strong>enlargement or &ldquo;bulge&rdquo; of a large blood vessel</strong></p><p>(aortic aneurysm or large vessel peripheral aneurysm).</p><p>-If you have experienced a previous episode of <strong>aortic dissection </strong>(a tear in the aorta wall).</p><p>-&nbsp; If you have a family history of <strong>aortic aneurysm or aortic dissection </strong>or other risk factors or predisposing conditions (e.g. connective tissue disorders such as Marfan syndrome, or vascular Ehlers-Danlos syndrome, or vascular disorders such as Takayasu arteritis, giant cell arteritis, Behcet&acute;s disease, high blood pressure, or known atherosclerosis).</p><p>-&nbsp; If you or any member of your family have <strong>glucose-6-phosphate dehydrogenase deficiency </strong>(a rare hereditary disease), tell your doctor, who will advise whether Viagacin is suitable for you.</p><p>&nbsp;</p><p>-&nbsp; If you have a <strong>complicated infection of the female upper genital tract </strong>(e.g. associated with an abscess of the fallopian tubes and ovaries or of the pelvis), for which your doctor considers an intravenous treatment necessary, treatment with Viagacin tablets is not appropriate.</p><p>-For the treatment of <strong>mild to moderate infections of the female upper genital tract </strong>your doctor should prescribe another antibiotic in addition to Viagacin. If there is&nbsp; no&nbsp; improvement&nbsp; in&nbsp; symptoms after 3 days of treatment, please consult your doctor.</p><p>&nbsp;</p><p>When taking Viagacin</p><p>-&nbsp; If you experience <strong>palpitations or irregular heart beat </strong>during the period of treatment, you should inform your doctor immediately. He/she may wish to perform an ECG to measure your heart rhythm.</p><p>-&nbsp; The <strong>risk of heart problems </strong>may increase with increase of the dose. Therefore, the recommended dosage should be followed.</p><p>There is a rare chance that you may experience a <strong>severe, sudden allergic reaction </strong>(an anaphylactic reaction/shock) even with the first dose. Symptoms include tightness in the chest, feeling dizzy, feeling sick or faint, or dizziness when standing up. <strong>If so, stop taking Viagacin and seek medical advice immediately.</strong></p><p>-&nbsp; Viagacin may cause a <strong>rapid and severe inflammation of the liver </strong>which could lead to life- threatening liver failure (including fatal cases, see section <strong>4. Possible side effects</strong>). If you suddenly feel unwell and/or are being sick and also have yellowing of the whites of the eyes, dark urine, itching of the skin, a tendency to bleed or liver induced disease&nbsp; of the brain (symptoms&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of a reduced liver function or a rapid and severe inflammation&nbsp; of&nbsp; the&nbsp; liver)&nbsp; <strong>please&nbsp; contact&nbsp; your doctor before taking any more tablets.</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>- </strong>If you develop a <strong>skin reaction or blistering / peeling of the skin and/or mucosal reactions </strong>(see section <strong>4. Possible side effects) </strong>contact your doctor immediately before you continue treatment.</p><p>-&nbsp;&nbsp; Quinolone antibiotics, including Viagacin, may cause <strong>convulsions</strong>. If this happens, stop taking Viagacin and contact your doctor immediately.</p><p>-&nbsp; You may experience <strong>symptoms of nerve damage (neuropathy) </strong>such as pain, burning, tingling, numbness and/or weakness especially in the feet and legs or hands and arms. If this happens, inform your doctor immediately prior to continuing treatment with Viagacin.</p><p>-&nbsp; You may experience <strong>mental health problems </strong>even when taking quinolone antibiotics, including</p><p>Viagacin, for the first time. In very rare cases depression or mental health problems have led to suicidal thoughts and self-injurious behaviour such as suicide attempts (see section <strong>4. Possible side effects</strong>). If you develop such reactions, stop taking Viagacin and inform your doctor immediately.</p><p>-&nbsp; You may develop <strong>diarrhoea </strong>whilst or after taking antibiotics including Viagacin. If this becomes severe or persistent or you notice that your stool contains blood or mucus you should <strong>stop taking Viagacin immediately and consult your doctor</strong>. You should not take medicines that stop or slow down bowel movement.</p><p>-&nbsp; Viagacin may cause <strong>pain and inflammation of your tendons</strong>, even within 48 hours of starting treatment and up to several&nbsp; months&nbsp; after&nbsp; discontinuing&nbsp; Viagacin&nbsp; therapy.&nbsp; The risk&nbsp; of&nbsp; inflammation and rupture of tendons is increased if you are elderly or if you are&nbsp;&nbsp; also taking corticosteroids. At the first sign of any pain or inflammation you should stop taking Viagacin, rest the</p><p>affected limb(s) and <strong>consult your doctor immediately. </strong>Avoid any unnecessary exercise, as this might increase the risk of a tendon rupture (see sections Do not take Viagacin<em>&hellip; </em>and 4. Possible side effects).</p><p>-If you feel sudden, severe pain in your abdomen, chest or back, go immediately to an emergency room.</p><p>-&nbsp; If you are elderly and have <strong>kidney problems </strong>make sure that you drink plenty whilst taking Viagacin. If you get dehydrated this may increase the risk of kidney failure.</p><p>&nbsp;</p><p>&nbsp;</p><p>-&nbsp; If your <strong>eyesight becomes impaired </strong>or if your eyes seem to be otherwise affected, consult an eye specialist immediately (see sections <strong>Driving and using machines </strong>and <strong>4. Possible side effects</strong>)</p><p>-&nbsp; Fluoroquinolone antibiotics may cause <strong>disturbances in blood sugar</strong>, including both a decrease in blood sugar below normal levels (hypoglycemia) and an increase in blood sugar above normal levels (hyperglycemia)(see section 4. Possible side effects). In patients treated with Viagacin, disturbances in blood sugar occurred predominantly in elderly diabetic patients receiving concomitant treatment with oral antidiabetic medicines that lower blood sugar (e. g. sulfonylurea) or with insulin. Loss of consciousness due to severe reduction in blood sugar (hypoglycaemic coma) have been reported.</p><p>If you suffer from diabetes, your blood sugar should be carefully monitored.</p><p>-&nbsp; Quinolone antibiotics may make your <strong>skin </strong>become more <strong>sensitive to sunlight or UV light</strong>. You should avoid prolonged exposure to sunlight or strong sunlight and should not use a sunbed or any other UV lamp while taking Viagacin.</p><p>-&nbsp;&nbsp; The efficacy of Viagacin in the treatment of severe burns, infections of deep tissue and diabetic foot infections with osteomyelitis (infections of the bone marrow) has not been established.</p><p>&nbsp;</p><p>Children and adolescents</p><p>Do not give this medicine to children and adolescents under the age of 18 because efficacy and safety have not been established for this age group (see section <strong>Do not take Viagacin</strong>).</p><p>&nbsp;</p><p>Other medicines and Viagacin</p><p>Tell your doctor or pharmacist about any other medicines that you are taking, took recently&nbsp;&nbsp; or might take.</p><p>&nbsp;</p><p>For Viagacin, be aware of the following:</p><p>-&nbsp;&nbsp; If you are taking Viagacin and other <strong>medicines that affect your heart&nbsp; </strong>there&nbsp; is&nbsp; an increased risk for altering your heart rhythm. Therefore, do not take Viagacin together with the following medicines:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that belong to the group of anti-arrhythmics (e.g. quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide)</p><p>&bull;&nbsp;&nbsp; antipsychotics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride)</p><p>&bull;&nbsp;&nbsp; tricyclic antidepressants</p><p>&bull;&nbsp; some antimicrobials (e.g. saquinavir, sparfloxacin, intravenous erythromycin, pentamidine, antimalarials particularly halofantrine)</p><p>&bull;&nbsp;&nbsp;&nbsp; some antihistamines (e.g. terfenadine, astemizole, mizolastine)</p><p>&bull;&nbsp;&nbsp; other medicines (e.g. cisapride, intravenous vincamine, bepridil and diphemanil).</p><p>&nbsp;</p><p>-&nbsp; You must tell your doctor if you are taking other medicines that can lower your blood potassium levels (e.g. some diuretics, some laxatives and enemas [high doses] or corticosteroids [anti- inflammatory drugs], amphotericin B) or cause a slow heart rate because these can also increase the risk of serious heart rhythm disturbances while taking Viagacin.</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Any <strong>medicine containing magnesium or aluminium </strong>(such as antacids for indigestion), <strong>iron, zinc or didanosine </strong>or any medicine containing <strong>sucralfate </strong>(to treat stomach disorders) can reduce the action of Viagacin tablets. Take your Viagacin tablet 6 hours before or after taking the other medicine.</p><p>&nbsp;</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Taking any medicine containing <strong>charcoal&nbsp; </strong>at the same time as Viagacin tablets reduces&nbsp;&nbsp;&nbsp;&nbsp; the action of Viagacin. It is recommended that these medicines are not used together.</p><p>-&nbsp;&nbsp;&nbsp; If you are currently taking <strong>drugs to thin your blood </strong>(oral anti-coagulants such as&nbsp; warfarin), it may be necessary for your doctor to monitor your blood clotting time.</p><p>&nbsp;</p><p>Viagacin with food and drink</p><p>Viagacin can be taken with or without food (including dairy products).</p><p>&nbsp;</p><p>Pregnancy, breast-feeding and fertility</p><p>&nbsp;</p><p>Do not take Viagacin if you are pregnant or breast-feeding.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Animal studies do not indicate that your fertility will be impaired by taking this medicine.</p><p>Driving and using machines</p><p>Viagacin may make you feel dizzy or light-headed, you may experience a sudden, transient loss of vision, or you may faint for a short period. If you are affected do not drive or operate machinery.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose for adults is one 400mg film-coated tablet once daily.</p><p>Viagacin tablets are for oral&nbsp; use. Swallow the tablet whole (to mask the bitter taste) and&nbsp;&nbsp;&nbsp;&nbsp; with plenty of liquid. You can take Viagacin with or without food. Try to take the tablet at approximately the same time each day.</p><p>The same dose can be taken by elderly patients, patients with a low bodyweight or in patients with kidney problems.</p><p>The time you will take Viagacin for depends on your infection. Unless your doctor tells you otherwise, your treatment will be as follows:</p><p>-&nbsp; for sudden worsening (acute exacerbation) of chronic bronchitis 5 - 10 days</p><p>-&nbsp; for infection of the lungs (pneumonia) except for pneumonia which starts during a stay in hospital 10 days.</p><p>-&nbsp; for acute infection of the sinuses (acute bacterial sinusitis) 7 days</p><p>-&nbsp; Mild to moderate infections of the female upper genital tract (pelvic inflammatory disease), including infection of the fallopian tubes and infection of the uterus mucous membrane 14 days</p><p>When Viagacin film-coated tablets are used to complete a course of therapy started with Viagacin solution for infusion, the recommended durations of use are:</p><p>&nbsp;</p><p>-&nbsp; Infection of the lungs (pneumonia) acquired outside the hospital 7 -14 days</p><p>Most patients with pneumonia were switched to oral treatment with Viagacin film-coated tablets within 4 days.</p><p>-&nbsp; Infections of the skin and soft tissue 7 -21 days</p><p>Most patients with infections of the skin and soft tissue were switched to oral treatment&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with Viagacin film-coated tablets within 6 days.</p><p>It is important that&nbsp; you complete the course of treatment&nbsp; even if you&nbsp; begin to feel better&nbsp; after a few days. If you stop taking Viagacin too soon your infection may not be completely cured and the infection may return or your condition may get worse. The bacteria causing&nbsp; your infection may become resistant to Viagacin.</p><p>&nbsp;</p><p>The recommended dose and duration of treatment should not be exceeded (see section</p><p><strong>2.&nbsp; </strong><strong>What you need to know before you take Viagacin, Warnings and precautions). If you take more Viagacin than you should</strong></p><p>If you take more than the prescribed one tablet a day, get <strong>medical help immediately</strong>. Try to take any remaining tablets, the packaging or this leaflet with you to show the doctor or pharmacist what you have taken.</p><p>&nbsp;</p><p>If you forget to take Viagacin</p><p>If you forget to take your tablet you should <strong>take it as soon as you remember on the same day</strong>. If you do not remember on&nbsp; the same day,&nbsp; take your normal dose (one tablet)&nbsp; on the&nbsp; next day. Do not take a double dose to make up for a forgotten dose.</p><p>If you are unsure about what to do ask your doctor or pharmacist.</p><p>&nbsp;</p><p>If you stop taking Viagacin</p><p>If you stop taking this medicine too soon your infection may not be completely cured. Talk to your doctor if you wish to stop taking your tablets before the end of the course of treatment.</p><p>&nbsp;</p><p>If you have any further questions about this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The <strong>most serious side effects </strong>observed during treatment with Viagacin are listed below:</p><p>If you notice</p><p>&bull;&nbsp;&nbsp;&nbsp; an abnormal fast heart rhythm (rare side effect)</p><p>&bull;&nbsp; that you suddenly start feeling unwell or notice yellowing of the whites of the eyes, dark urine, itching of the skin, a tendency to bleed or disturbances of thought or wakefulness (these can be signs and symptoms of fulminant inflammation of the liver potentially leading to life-threating liver failure (very rare side effect, fatal cases have been observed))</p><p>&bull;&nbsp; alterations of the skin and mucous membranes like painful blisters in the mouth/nose or at the penis/vagina (Stevens-Johnson syndrome or toxic epidermal necrolysis) (very rare side effects, potentially life threatening)</p><p>&bull;&nbsp; inflammation of blood vessels (signs could be red spots on your skin, usually on your lower legs or effects like joint pain) (very rare side effect)</p><p>&bull;&nbsp; a severe, sudden generalised allergic reaction incl. very rarely a life-threatening shock (e.g. difficulty in breathing, drop of blood pressure, fast pulse) (rare side effect)</p><p>&bull;&nbsp;&nbsp; swelling incl. swelling of the airway (rare side effect, potentially life-threatening)</p><p>&bull;&nbsp;&nbsp; convulsions (rare side effect)</p><p>&bull;&nbsp;&nbsp; troubles associated with the nervous system such as pain, burning, tingling, numbness and/or weakness in extremities (rare side effect)</p><p>&bull;&nbsp; depression (in very rare cases leading to self-harm, such as suicidal ideations/thoughts, or suicide attempts) (rare side effect)</p><p>&bull; insanity (potentially leading to self-harm, such as suicidal ideations/thoughts, or suicide attempts) (very rare side effect)</p><p>&bull; severe diarrhoea containing blood and/or mucus (antibiotic associated colitis incl. pseudomembranous colitis), which in very rare circumstances, may develop into complications that are life-threatening (rare side effects)</p><p>&bull; pain and swelling of the tendons (tendonitis) (rare side effect) or a tendon rupture (very rare side effect)</p><p>&nbsp;</p><p><strong>stop taking Viagacin and tell your doctor immediately </strong>as you may need urgent medical advice.</p><p>&nbsp;</p><p>In addition, if you notice</p><p>&bull;&nbsp; transient loss of vision (very rare side effect),</p><p>&bull;&nbsp; discomfort or pain to the eyes, especially due to light exposure (very rare to rare side effect)</p><p>contact an eye specialist immediately.</p><p>&nbsp;</p><p>If you have experienced life-threatening irregular heart beat (Torsade de Pointes) or stopping of heart beat while taking Viagacin (very rare side effects), <strong>tell your treating doctor immediately that you have taken Viagacin and do not restart the treatment.</strong></p><p>A worsening of the&nbsp; symptoms of&nbsp; myasthenia gravis has been observed in very rare cases.&nbsp; If&nbsp;&nbsp;&nbsp; this happens, <strong>consult your doctor immediately</strong>.</p><p>&nbsp;</p><p>If you suffer from diabetes and you notice that your blood sugar is increased or decreased (rare or very rare side effect), <strong>inform your doctor immediately</strong>.</p><p>&nbsp;</p><p>If you are elderly with existing kidney problems and you notice&nbsp; decrease&nbsp; in&nbsp; urine&nbsp; output,&nbsp; swelling in your legs, ankles or feet, fatigue, nausea,&nbsp; drowsiness,&nbsp; shortness&nbsp; of&nbsp; breath&nbsp; or&nbsp; confusion (these can be signs and symptoms of kidney failure, a rare side effect), <strong>consult your doctor immediately.</strong></p><p><strong>Other side effects </strong>which have been observed during treatment with Viagacin are listed below by how likelythey are:</p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach and abdominal ache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of a special liver enzyme in the blood (transaminases)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections caused by resistant bacteria or fungi e.g. oral and vaginal infections caused by Candida</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change of the heart rhythm (ECG) in patients with low blood potassium level.</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><p>&nbsp;</p><p>&bull;&nbsp; Rash</p><p>&bull;&nbsp; stomach upset (indigestion/heartburn)</p><p>&bull;&nbsp; changes in taste (in very rare cases loss of taste)</p><p>&bull;&nbsp; sleep problems (predominantly sleeplessness)</p><p>&bull;&nbsp; increase of a special liver enzyme in the blood (gamma-glutamyl-transferase&nbsp; and/or&nbsp; alkaline phosphatase)</p><p>&bull;&nbsp; low number of special white blood cells (leukocytes, neutrophils)</p><p>&bull;&nbsp; constipation</p><p>&bull;&nbsp; itching</p><p>&bull;&nbsp; sensation of dizziness (spinning or falling over)</p><p>&bull;&nbsp; sleepiness</p><p>&bull;&nbsp; wind</p><p>&bull;&nbsp; change of the heart rhythm (ECG)</p><p>&bull;&nbsp; impaired liver function (incl. increase of a special liver enzyme in the blood (LDH))</p><p>&bull;&nbsp; decreased appetite and food intake</p><p>&bull;&nbsp; low white blood cells count</p><p>&bull;&nbsp; aches and pains such as back, chest, pelvic and extremities pains</p><p>&bull;&nbsp; increase of special blood cells necessary for blood clotting</p><p>&bull;&nbsp; sweating</p><p>&bull;&nbsp; increased specialised white blood cells (eosinophils)</p><p>&bull;&nbsp; anxiety</p><p>&bull;&nbsp; feeling unwell (predominantly weakness or tiredness)</p><p>&bull;&nbsp; shaking</p><p>&bull;&nbsp; joint pain</p><p>&nbsp;</p><p>&bull;&nbsp; palpitations</p><p>&bull;&nbsp; irregular and fast heart beat</p><p>&bull;&nbsp; difficulty in breathing incl. asthmatic conditions</p><p>&bull;&nbsp; increase of a special digestive enzyme in the blood (amylase)</p><p>&bull;&nbsp; restlessness / agitation</p><p>&nbsp;</p><p>&bull;&nbsp; tingling sensation (pins and needles) and/or numbness</p><p>&bull;&nbsp; skin hives</p><p>&bull;&nbsp; widening of blood vessels</p><p>&bull;&nbsp; confusion and disorientation</p><p>&bull;&nbsp; decrease of special blood cells necessary for blood clotting</p><p>&bull;&nbsp; visual disturbances incl. double and blurred vision</p><p>&bull;&nbsp; decreased blood clotting</p><p>&bull;&nbsp; increased blood lipids (fats)</p><p>&nbsp;</p><p>&bull;&nbsp; low red blood cell count</p><p>&bull;&nbsp; muscle pain</p><p>&bull;&nbsp; allergic reaction</p><p>&bull;&nbsp; increase of bilirubin in the blood</p><p>&bull;&nbsp; inflammation of the stomach</p><p>&bull;&nbsp; dehydration</p><p>&bull;&nbsp; severe heart rhythm abnormalities</p><p>&bull;&nbsp; dry skin</p><p>&bull;&nbsp; angina pectoris</p><p>&nbsp;</p><p><strong>Rare </strong>(may affect up to 1 in 1,000 people)</p><p>&bull;&nbsp; muscle twitching</p><p>&nbsp;</p><p>&bull;&nbsp; muscle cramp</p><p>&nbsp;</p><p>&bull;&nbsp; hallucination</p><p>&nbsp;</p><p>&bull;&nbsp; high blood pressure</p><p>&nbsp;</p><p>&bull;&nbsp; swelling (of the hands, feet, ankles, lips, mouth, throat)</p><p>&nbsp;</p><p>&bull;&nbsp; low blood pressure</p><p>&nbsp;</p><p>&bull;&nbsp; kidney impairment (incl. increase in special kidney laboratory test results like urea and creatinine)</p><p>&nbsp;</p><p>&bull;&nbsp; inflammation of the liver</p><p>&nbsp;</p><p>&bull;&nbsp; inflammation of the mouth</p><p>&nbsp;</p><p>&bull;&nbsp; ringing/noise in the ears</p><p>&nbsp;</p><p>&bull;&nbsp; jaundice (yellowing of the whites of the eyes or skin)</p><p>&nbsp;</p><p>&bull;&nbsp; impairment of skin sensation</p><p>&nbsp;</p><p>&bull;&nbsp; abnormal dreams</p><p>&nbsp;</p><p>&bull;&nbsp; disturbed concentration</p><p>&nbsp;</p><p>&bull;&nbsp; difficulty in swallowing</p><p>&nbsp;</p><p>&bull;&nbsp; changes in smell (incl. loss of smell)</p><p>&nbsp;</p><p>&bull;&nbsp; balance disorder and poor co-ordination (due to dizziness)</p><p>&nbsp;</p><p>&bull;&nbsp; partial or total loss of memory</p><p>&nbsp;</p><p>&bull;&nbsp; hearing impairment including deafness (usually reversible)</p><p>&nbsp;</p><p>&bull;&nbsp; increased blood uric acid</p><p>&nbsp;</p><p>&bull;&nbsp; emotional instability</p><p>&nbsp;</p><p>&bull;&nbsp; impaired speech</p><p>&nbsp;</p><p>&bull;&nbsp; fainting</p><p>&nbsp;</p><p>&bull;&nbsp; muscle weakness</p><p>&nbsp;</p><p><strong>Very rare </strong>(may affect up to 1 in 10,000 people)</p><p>&bull;&nbsp; inflammation of joints</p><p>&bull;&nbsp; abnormal heart rhythms</p><p>&bull;&nbsp; increase of skin sensitivity</p><p>&bull;&nbsp; a feeling of self-detachment (not being yourself)</p><p>&bull;&nbsp; increased blood clotting</p><p>&bull;&nbsp; muscle rigidity</p><p>&bull;&nbsp; significant decrease of special white blood cells (agranulocytosis)</p><p>&nbsp;</p><p>Further more; there have been very rare cases of the following side effects reported following treatment with other quinolone antibiotics, which might possibly also occur during treatment with Viagacin:</p><p>&bull;&nbsp; Raised pressure in the skull (symptoms include headache, visual problems including blurred vision, &ldquo;blind&rdquo; spots, double vision, loss of vision)</p><p>&bull;&nbsp; Increased blood sodium levels</p><p>&bull;&nbsp; Increased blood calcium levels</p><p>&bull;&nbsp; A special type of reduced red blood cell count (haemolytic anaemia)</p><p>&bull;&nbsp; Muscle reactions with muscle cell damage</p><p>&bull;&nbsp; Increased sensitivity of the skin to sunlight or UV light.</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong><em>&nbsp;&bull; </em></strong><strong>Saudi Arabia<em>:</em></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website:&nbsp;https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>o Other GCC States:</em></strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30◦C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children. Store below 30◦C.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is shown on the packaging. The expiry date refers to the last day of the month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep the blister in the outer carton in order to protect from light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater of household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Viagacin Tablets 400 contains</strong></p><p>The active substance is Viagacin</p><p>Each Film coated tablet contains Viagacin Ph.Eur 436.33mg Equivalent to Viagacin 400 mg</p><p>&nbsp;</p><p>The other ingredients are: Cellulose Microcrystalline, Croscarmellose sodium, Silica colloidal anhydrous, Povidone K-30, Magnesium stearate.</p><p>&nbsp;</p><p>Film Coating Composition: Hypromellose ( 62.500%), T i t a n i u m Dioxide(28.730%), Macrogol(6.250%), Iron oxide Red (2.500%), Iron oxide yellow (0.020%).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Viagacin Tablets 400 looks like? Viagacin Tablets 400mg

Pink coloured, capsule shaped, biconvex, film coated tablets, debossed with ‘80’ on one side and ‘I’ on the other side.

How supplied:

Viagacin 400mg tablets are supplied in 1 x 5’s and 1 X 7’s Alu-Alu Blister pack. Not all pack sizes may be marketed.

Marketing Authorisation Holder


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Saudi Amarox Industrial Company</p><p>Aljameah Street, Malaz quarter, Riyadh 11441 Saudi Arabia</p><p>Tel: +966 11 477 221.</p><p>Manufacturer</p><p>Hetero Labs Limited Unit V Telangana, India</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April, 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي فياجاسين أقراص على المادة الفعالة موكسيفلوكساسين هيدروكلوريد، والذي ينتمي إلى مجموعة من المضادات الحيوية تسمى الفلوروكينولونات. حيث يعمل فياجاسين أقراص عن طريق قتل البكتيريا التي تسبب الالتهابات.</p><p dir="RTL">يستخدم فياجاسين أقراص في المرضى الذين تتراوح أعمارهم بين 18 عامًا فما فوق لعلاج الالتهابات البكتيرية التالية عندما تسببها البكتيريا التي يعمل ضدها الموكسيفلوكساسين. يجب استخدام فياجاسين أقراص فقط لعلاج هذه الالتهابات عندما لا يمكن استخدام المضادات الحيوية المعتادة أو لم تنجح.</p><p dir="RTL">عدوى الجيوب الأنفية، وتفاقم التهاب الشعب الهوائية على المدى الطويل أو التهاب الرئتين المكتسب خارج المستشفى (باستثناء الحالات الشديدة).</p><p dir="RTL">التهابات خفيفة إلى معتدلة في الجهاز التناسلي العلوي للإناث (مرض التهاب الحوض)، بما في ذلك الالتهابات في قناة فالوب والتهابات الغشاء المخاطي في الرحم.</p><p dir="RTL">أقراص فياجاسين لا تكفي وحدها لعلاج هذا النوع من العدوى. لذلك، يجب أن يصف طبيبك مضادًا حيويًا آخر بالإضافة إلى أقراص فياجاسين أقراص لعلاج التهابات الجهاز التناسلي العلوي للإناث (انظر القسم 2. ماذا تحتاج إلى معرفته قبل أن تتناول فياجاسين أقراص، التحذيرات والاحتياطات، تحدث إلى طبيبك قبل تناول فياجاسين أقراص).</p><p dir="RTL">إذا كانت الالتهابات البكتيرية التالية قد أظهرت تحسنا أثناء العلاج الأولي باستخدام محلول فياجاسين أقراص للتسريب، فقد يصف الطبيب أيضًا أقراص فياجاسين أقراص لاستكمال مسار العلاج:</p><p dir="RTL">إصابة الرئتين (الالتهاب الرئوي) المكتسبة خارج المستشفى، والتهابات الجلد والأنسجة الرخوة. لا ينبغي أن تستخدم أقراص فياجاسين أقراص لبدء العلاج لأي نوع من أنواع التهابات الجلد والأنسجة الرخوة أو في التهابات شديدة في الرئتين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتصل بطبيبك إذا كنت غير متأكد مما إذا كنت تنتمي إلى مجموعة من المرضى الموصوفة أدناه.</p><p dir="RTL"><strong>لا تقم باستعمال فياجاسين أقراص:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه موكسيفلوكساسين هيدروكلوريد أو أي مضادات حيوية أخرى من مجموعة الكينولون أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حاملاً أو ترضعين طفلك طبيعيا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان عمرك أقل من 18 عامًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد واجهت من قبل مشاكل في الأوتار المتعلقة بالمعالجة بمضادات الكينولون (انظر القسم التحذيرات والاحتياطات ... والقسم 4. الآثار الجانبية المحتملة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد ولدت مع أو لديك:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي حالة تعاني من إيقاع القلب الغير طبيعي (حيث تظهر من خلال تخطيط القلب، والتسجيل الكهربائي للقلب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم توازن الملح في الدم (وخاصة انخفاض مستويات البوتاسيوم أو الماغنيسيوم في الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيقاع القلب البطيء جدًا (يُطلق عليه &quot;بطء القلب&quot;)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف القلب (فشل القلب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تاريخ من إيقاعات القلب غير طبيعية أو إذا كنت تتناول أدوية أخرى تؤدي إلى تغييرات غير طبيعية لتخطيط القلب (انظر القسم أدوية أخرى وفياجاسين أقراص). هذا لأن فياجاسين أقراص يمكن أن يسبب تغييرات في نتائج تخطيط القلب، حيث يحدث امتداد لفواصل QT، أي التوصيل المتأخر للإشارات الكهربائية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض كبدي حاد أو زيادة إنزيمات الكبد (ناقلة الأمين) أعلى5 مرات من الحد الطبيعي.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong><strong> </strong></p><p dir="RTL">استشر طبيبك قبل تناول فياجاسين أقراص في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فياجاسين أقراص يمكن أن يغير تخطيط قلبك، خاصة إذا كنت أنثى، أو إذا كنت مسنًا. إذا كنت تتناول حاليا أي دواء يقلل من مستويات البوتاسيوم في الدم، استشر طبيبك قبل تناول فياجاسين أقراص (انظر أيضا الأقسام لا تتناول أدوية أخرى وفياجاسين أقراص).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض الصرع أو لديك حالة تجعلك عرضة للتشنجات، تحدث إلى طبيبك قبل تناول فياجاسين أقراص.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي مشاكل صحية نفسية أو سبق أن عانيت منها، استشر طبيبك قبل تناول فياجاسين أقراص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الوهن العضلي الوبيل (إرهاق عضلي غير طبيعي يؤدي إلى الضعف وفي الحالات الخطيرة الشلل)، فقد يؤدي تناول فياجاسين أقراص إلى تفاقم أعراض مرضك. إذا كنت تعتقد أنك تعاني من ذلك، استشر طبيبك على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تم تشخيصك بتضخم أو &quot;انتفاخ&quot; الأوعية الدموية الكبيرة (تمدد الأوعية الدموية الأبهري أو تمدد الأوعية الدموية المحيطية بالأوعية الدموية الكبيرة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من حلقة سابقة من تسلخ الشريان الأبهر (تسرب دموي في جدار الشريان الأورطي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ عائلي من تمدد&nbsp;الأوعية الدموية الأبهري أو تسلخ الشريان الأبهر أو عوامل الخطر الأخرى أو الظروف المؤهبة (مثل اضطرابات الأنسجة الضامة مثل متلازمة مارفان أو الأوعية الدموية) متلازمة&nbsp;إهلرز-دانلوس، أو اضطرابات الأوعية الدموية مثل التهاب الشرايين تاكاياسو، التهاب الشريان الصُّدْغِيّ، متلازمة بهجت، ارتفاع ضغط الدم، أو تصلب الشرايين المعروف).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أنت أو أي فرد من أفراد عائلتك مصابًا بنقص هيدروجيناز الجلوكوز -6 فوسفات (مرض وراثي نادر)، أخبر طبيبك الذي سيبلغك بما إذا كانت فياجاسين أقراص مناسبة لك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك التهاب معقد في الجهاز التناسلي العلوي للإناث (على سبيل المثال المرتبط بخراج قناة فالوب والمبيض أو الحوض)، الذي يعتبر طبيبك في هذه الحالة أن العلاج عن طريق الوريد ضروري، فإن العلاج بأقراص فياجاسين أقراص غير مناسب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للعلاج من التهابات خفيفة إلى معتدلة في الجهاز التناسلي العلوي للإناث يجب أن يصف طبيبك مضاد حيوي آخر بالإضافة إلى فياجاسين أقراص. إذا لم يكن هناك تحسن في الأعراض بعد 3 أيام من العلاج، فيرجى استشارة الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>عند تناول فياجاسين أقراص</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من خفقان بالقلب أو عدم انتظام ضربات القلب خلال فترة العلاج، يجب عليك إخبار طبيبك على الفور. هو / هي قد ترغب في إجراء تخطيط القلب لقياس إيقاع القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تزداد مخاطر الإصابة بأمراض القلب مع زيادة الجرعة. لذلك، يجب اتباع الجرعة الموصي بها.</p><p dir="RTL">هناك فرصة نادرة لتعرضك لرد فعل تحسسي حاد ومفاجئ (تفاعل / صدمة تأقية) حتى مع الجرعة الأولى. تشمل الأعراض ضيق في الصدر، والشعور بالدوار، والشعور بالغثيان أو الإغماء، أو الدوار عند الوقوف. إذا كان الأمر كذلك، توقف عن تناول فياجاسين أقراص واطلب المشورة الطبية على الفور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتسبب تناول فياجاسين أقراص في حدوث التهاب سريع وشديد في الكبد يمكن أن يؤدي إلى فشل الكبد الذي يهدد الحياة (بما في ذلك الحالات القاتلة، انظر القسم 4. الآثار الجانبية المحتملة). إذا شعرت فجأة بتوعك و / أو كنت مريضًا ولديك أيضًا اصفرار بياض العينين، والبول الداكن، وحكة الجلد، وميل إلى النزيف أو مرض الكبد الناجم عن مرض الكبد (أعراض انخفاض وظائف الكبد أو التهاب سريع وحاد في الكبد) يرجى الاتصال بطبيبك قبل تناول أي أقراص أخرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من رد فعل الجلد أو تقرحات / تقشر الجلد و / أو ردود الفعل المخاطية (انظر القسم 4. الآثار الجانبية المحتملة) اتصل بطبيبك مباشرة قبل مواصلة العلاج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية التي تنتمي إلى مجموعة الكينولون، بما في ذلك فياجاسين أقراص، قد تسبب في التشنجات. إذا حدث هذا، توقف عن تناول فياجاسين أقراص واتصل بطبيبك على الفور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تواجه أعراض تلف الأعصاب (الاعتلال العصبي) مثل الألم، والحرقة، وخز، وخدر و / أو ضعف خاصة في القدمين والساقين أو اليدين والذراعين. في حالة حدوث ذلك، أخبر طبيبك مباشرة قبل مواصلة العلاج باستخدام فياجاسين أقراص.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تواجه مشكلات في الصحة العقلية حتى عند تناول المضادات الحيوية التي تنتمي إلى مجموعة الكينولون، بما في ذلك فياجاسين أقراص، لأول مرة. في حالات نادرة جدًا، أدى الاكتئاب أو مشاكل الصحة العقلية إلى أفكار انتحارية وسلوك ضار ذاتيًا مثل محاولات الانتحار (انظر القسم 4. الآثار الجانبية المحتملة). إذا واجهت مثل هذه التفاعلات، فتوقف عن تناول فياجاسين أقراص وأبلغ طبيبك على الفور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تصاب بالإسهال أثناء أو بعد تناول المضادات الحيوية بما في ذلك فياجاسين أقراص. إذا أصبح هذا شديدًا أو مستمرًا أو لاحظت أن البراز يحتوي على دم أو مخاط، يجب عليك التوقف عن تناول فياجاسين أقراص على الفور واستشارة الطبيب. يجب عدم تناول الأدوية التي توقف أو تبطئ حركة الأمعاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يسبب فياجاسين أقراص الألم والتهاب الأوتار، حتى في غضون 48 ساعة من بدء العلاج وحتى عدة أشهر بعد التوقف عن العلاج بتناول. يزداد خطر التهاب وتمزق الأوتار إذا كنت مسنًا أو إذا كنت تتناول أيضًا الستيرويدات القشرية. في أول أعراض مثل أي ألم أو التهاب، يجب عليك التوقف عن تناول فياجاسين أقراص، قم باراحة الأطراف المصابة واستشر طبيبك على الفور. تجنب أي تمرين غير ضروري، لأن هذا قد يزيد من خطر تمزق الأوتار (انظر الأقسام لا تتناول فياجاسين أقراص ... و 4. الآثار الجانبية المحتملة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا شعرت بألم شديد ومفاجئ في البطن أو الصدر أو الظهر، انتقل على الفور إلى غرفة الطوارئ.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مسنًا وتعاني من مشاكل في الكلى، فتأكد من الشرب كثيرا أثناء تناول فياجاسين أقراص. إذا أصبت بالجفاف، فقد يزيد هذا من خطر الفشل الكلوي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبح بصرك ضعيفًا أو إذا كانت عيناك قد تأثرت بطريقة أخرى، فاستشر أخصائي العيون على الفور (انظر الأقسام القيادة واستخدام الآلات و 4. الآثار الجانبية المحتملة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تسبب المضادات الحيوية للفلوروكينولون اضطرابات لنسبة السكر في الدم، بما في ذلك انخفاض السكر في الدم عن المستويات الطبيعية (نقص السكر في الدم) وزيادة السكر في الدم عن المستويات الطبيعية (ارتفاع السكر في الدم) (انظر القسم 4. الآثار الجانبية المحتملة). في المرضى الذين عولجوا بـتناول فياجاسين أقراص، حدثت اضطرابات في نسبة السكر في الدم في الغالب عند مرضى السكري المسنين الذين يتلقون علاجًا مصاحبًا عن طريق الأدوية المضادة لمرض السكر عن طريق الفم التي تخفض نسبة السكر في الدم (مثل السلفونيل يوريا) أو بالأنسولين. تم الإبلاغ عن فقدان الوعي بسبب الانخفاض الحاد في نسبة السكر في الدم (غيبوبة سكر الدم).</p><p dir="RTL">إذا كنت تعاني من مرض السكري، فيجب مراقبة نسبة السكر في الدم لديك بعناية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات التي تنتمي إلى مجموعة الكينولون قد تجعل جلدك أكثر حساسية لأشعة الشمس أو الأشعة فوق البنفسجية. يجب تجنب التعرض الطويل لأشعة الشمس أو أشعة الشمس القوية ويجب عدم استخدام سرير الشمس أو أي مصباح UV آخر أثناء تناول فياجاسين أقراص.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لم تثبت فعالية فياجاسين أقراص في علاج الحروق الشديدة والتهابات الأنسجة العميقة والتهابات القدم المصابة بالتهاب العظم والنقي.</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">يجب عدم استخدام هذا الدواء للأطفال والمراهقين دون سن 18 لأن الفعالية والأمان لم يتم تحديدهما لهذه الفئة العمرية (انظر القسم التوقف عن تناول فياجاسين أقراص).</p><p dir="RTL"><strong>تناول أدوية أخرى مع فياجاسين أقراص </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي عن أي أدوية أخرى تتناولها أو تناولتها مؤخرًا أو قد تتناولها.</p><p dir="RTL"><strong>بالنسبة إلى فياجاسين أقراص، كن على دراية بما يلي:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول فياجاسين أقراص وغيرها من الأدوية التي تؤثر على قلبك، فهناك خطر متزايد لتغيير إيقاع القلب. لذلك، لا تتناول فياجاسين أقراص مع الأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تنتمي إلى مجموعة مضادات عدم انتظام ضربات القلب (مثل الكينيدين، الهيدروكينيدين، ديسوبيراميد، أميودارون، السوتالول، دوفيتيليد، إيبوتيليد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الذهان (مثل الفينوثيازين، البيموزيد، السرتيندول، هالوبيريدول، السلتوبريد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الاكتئاب ثلاثية الحلقات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مضادات الميكروبات (على سبيل المثال ساكوينافير، سبارفلوكساسين، الإريثروميسين في الوريد، البنتاميدين، مضادات الملاريا وخاصة الهالوفانترين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مضادات الهيستامين (مثل تيرفينادين، استيزميزول، ميزولاستين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى (مثل سيسابريد وفينكامين عن طريق الوريد وبيبريل وديفانيل).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب إخبار طبيبك إذا كنت تتناول أدوية أخرى يمكن أن تخفض مستويات البوتاسيوم في الدم (مثل بعض مدرات البول وبعض المسهلات والحقن الشرجية [بجرعات عالية] أو الكورتيكوستيرويدات [الأدوية المضادة للالتهابات] أو الأمفوتريسين B) أو تسبب بطىء معدل ضربات القلب لأن هذه يمكن أن تزيد من خطر حدوث اضطرابات خطيرة في ضربات القلب أثناء تناول فياجاسين أقراص.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي دواء يحتوي على الماغنيسيوم أو الألومنيوم (مثل مضادات الحموضة لعسر الهضم) أو الحديد أو الزنك أو ديدانوزين أو أي دواء يحتوي على سوكرالفات (لعلاج اضطرابات المعدة) يمكن أن يقلل من عمل أقراص فياجاسين أقراص. يجب تناول فياجاسين أقراص قبل 6 ساعات من تناول الدواء الآخر أو بعده.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول أي دواء يحتوي على الفحم في نفس الوقت مع أقراص فياجاسين قد يقلل من تأثير فياجاسين أقراص. يوصى بعدم استخدام هذه الأدوية معًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتعاطى الأدوية في الوقت الحالي لسيولة الدم (مضادات التخثر الفموية مثل الوارفارين)، فقد يكون من الضروري للطبيب مراقبة وقت تخثر الدم لديك.</p><p dir="RTL"><strong>تناول فياجاسين أقراص مع الطعام والشراب</strong></p><p dir="RTL">يمكن تناول فياجاسين أقراص مع أو بدون الطعام (بما في ذلك منتجات الألبان).</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">يجب عدم تناول فياجاسين أقراص إذا كنت حاملاً أو مرضعة.</p><p dir="RTL">إذا كنت حاملاً أو مرضعة، تعتقدين أنك قد تكون حاملاً أو تخططين لإنجاب طفل، اسأل طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL">لا تشير الدراسات على الحيوانات إلى أن خصوبتك ستضعف بسبب تناول هذا الدواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">تناول فياجاسين أقراص قد يجعلك تشعر بالدوار أو الدوخة، وقد تواجه فقدًا مفاجئًا وعابرًا للرؤية، أو قد يغمى عليك لفترة قصيرة. إذا كنت متأثرا بذلك فلا تقود السيارة أو تشغل الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائما على تناول هذا الدواء تماما كما أخبر طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">الجرعة الموصي بها للبالغين هي قرص واحدة مغلف بطبقة رقيقة 400 ملغم مرة واحدة يوميًا.</p><p dir="RTL">أقراص فياجاسين أقراص مخصصة للاستخدام عن طريق الفم. يجب ابتلاع القرص بالكامل (لإخفاء الطعم المر) وبكميات كبيرة من السائل. يمكنك أن تتناول فياجاسين أقراص مع أو بدون طعام. حاول أن تتناول الأقراص في نفس الوقت تقريبًا كل يوم.</p><p dir="RTL">يمكن تناول نفس الجرعة من قبل المرضى المسنين أو المرضى الذين يعانون من انخفاض وزن الجسم أو في المرضى الذين يعانون من مشاكل في الكلى.</p><p dir="RTL">يعتمد الوقت الذي تستغرقه في تناول فياجاسين أقراص على شدة العدوى لديك. ما لم يخبرك طبيبك بخلاف ذلك، سيكون علاجك على النحو التالي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج التفاقم المفاجئ (تفاقم حاد) من التهاب الشعب الهوائية المزمن 5 - 10 أيام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج العدوى في الرئتين (الالتهاب الرئوي) باستثناء الالتهاب الرئوي الذي يبدأ خلال الإقامة في المستشفى 10 أيام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج العدوى الحادة للجيوب الأنفية (التهاب الجيوب الأنفية البكتيري الحاد) 7 أيام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج الالتهابات الخفيفة إلى المعتدلة في الجهاز التناسلي العلوي للإناث (مرض التهاب الحوض)، بما في ذلك عدوى قناة فالوب وعدوى الغشاء المخاطي في الرحم 14 يومًا</p><p dir="RTL">عند استخدام فياجاسين أقراص لاستكمال دورة علاجية بدأت بمحلول فياجاسين أقراص للتسريب، فإن فترات الاستخدام الموصي بها هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج إصابة الرئتين (الالتهاب الرئوي) المكتسبة خارج المستشفى من 7 إلى 14 يومًا</p><p dir="RTL">تم تحويل معظم المرضى الذين يعانون من الالتهاب الرئوي إلى العلاج عن طريق الفم باستخدام فياجاسين أقراص في غضون 4 أيام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج التهابات الجلد والأنسجة الرخوة 7-21 يوم</p><p dir="RTL">تم تحويل معظم المرضى الذين يعانون من التهابات الجلد والأنسجة الرخوة إلى العلاج عن طريق الفم باستخدام فياجاسين أقراص في غضون 6 أيام.</p><p dir="RTL">من المهم أن تكمل مسار العلاج حتى لو بدأت تشعر بالتحسن بعد بضعة أيام. إذا توقفت عن تناول فياجاسين أقراص في وقت مبكر جدًا، فقد لا يتم علاج العدوى تمامًا وقد تعود العدوى أو قد تسوء حالتك. قد تصبح البكتيريا المسببة للعدوى مقاومة لأقراص فياجاسين.</p><p dir="RTL">يجب عدم تجاوز الجرعة الموصي بها ومدة العلاج (انظر القسم 2. ما تحتاج إلى معرفته قبل تناول فياجاسين أقراص، التحذيرات والاحتياطات).</p><p dir="RTL"><strong>الجرعة الزائدة من فياجاسين أقراص</strong></p><p dir="RTL">إذا تناولت جرعة أكثر من الأقراص الموصوفة يوميًا، فيجب الحصول على مساعدة طبية على الفور. حاول أن تأخذ أي أقراص متبقية أو العبوة أو هذه النشرة معك لإظهار ما تناولته للطبيب أو الصيدلي.</p><p dir="RTL"><strong>نسيان تناول فياجاسين أقراص</strong></p><p dir="RTL">إذا نسيت تناول الأقراص، فيجب أن تتناولها حالما تتذكر ذلك في نفس اليوم. إذا كنت لا تتذكر في نفس اليوم، تناول الجرعة العادية (قرص واحد) في اليوم التالي. لا تتناول جرعة مضاعفة لتعويض جرعة منسية.</p><p dir="RTL">إذا لم تكن متأكدًا مما يجب عليك فعله اسأل طبيبك أو الصيدلي.</p><p dir="RTL"><strong>التوقف عن تناول فياجاسين أقراص</strong></p><p dir="RTL">إذا توقفت عن تناول هذا الدواء في وقت مبكر جدًا، فقد لا يتم علاج العدوى تمامًا. تحدث إلى طبيبك إذا كنت ترغب في التوقف عن تناول أقراصك قبل نهاية فترة العلاج.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حصول الجميع عليها. الآثار الجانبية الأكثر خطورة التي لوحظت أثناء العلاج بتناول فياجاسين أقراص مدرجة أدناه، إذا لاحظت:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات القلب السريعة غير الطبيعية (الآثار الجانبية النادرة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أن تبدأ فجأة في الشعور بالتعب أو يلاحظ اصفرار بياض العينين، والبول الداكن، وحكة الجلد، والميل إلى النزيف أو اضطرابات الفكر أو اليقظة (قد تكون هذه علامات وأعراض الالتهاب الكبدي المؤدي إلى فشل الكبد) الذي يهدد الحياة (الآثار الجانبية النادرة للغاية، وقد لوحظت حالات قاتلة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في الجلد والأغشية المخاطية مثل ظهور بثور مؤلمة في الفم / الأنف أو في القضيب / المهبل (متلازمة ستيفنز جونسون أو تنخر البشرة السمي) (آثار جانبية نادرة جدًا، يحتمل أن تهدد الحياة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية (يمكن أن تكون البقع الحمراء على جلدك، وعادة على أسفل الساقين أو آثار مثل آلام المفاصل) (آثار جانبية نادرة جدا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي شديد مفاجئ معمم. نادرًا ما تكون على شكل صدمة تهدد الحياة (مثل صعوبة في التنفس وانخفاض ضغط الدم والنبض السريع) (تأثير جانبي نادر)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الشعب الهوائية (تأثير جانبي نادر، يحتمل أن يهدد الحياة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنجات (الآثار الجانبية النادرة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المشاكل المرتبطة بالجهاز العصبي مثل الألم، حرقان، وخز، وخدر و / أو ضعف في الأطراف (تأثير جانبي نادر)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب (في حالات نادرة للغاية تؤدي إلى إيذاء النفس، مثل الأفكار الانتحارية، أو محاولات الانتحار) (الآثار الجانبية النادرة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجنون (يحتمل أن يؤدي إلى إيذاء النفس، مثل الأفكار الانتحارية، أو محاولات الانتحار) (الآثار الجانبية النادرة جدًا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال الحاد الذي يحتوي على الدم و / أو المخاط (التهاب القولون المرتبط بتناول المضادات الحيوية بما في ذلك التهاب القولون الغشائي الكاذب)، والذي في حالات نادرة جدًا، قد يتطور إلى مضاعفات تهدد الحياة (آثار جانبية نادرة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم وتورم الأوتار (التهاب الأوتار) (تأثير جانبي نادر) أو تمزق في الأوتار (تأثير جانبي نادر للغاية)</p><p dir="RTL">توقف عن تناول فياجاسين أقراص وأخبر طبيبك على الفور لأنك قد تحتاج إلى مشورة طبية عاجلة.</p><p dir="RTL">بالإضافة إلى ذلك، إذا لاحظت</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان عابر للرؤية (تأثير جانبي نادر للغاية)،</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إزعاج أو ألم في العينين، خاصة بسبب التعرض للضوء (نادر جدًا إلى الآثار الجانبية النادرة) <strong>اتصل بأخصائي العيون على الفور.</strong></p><p dir="RTL">إذا كنت تعاني من عدم انتظام ضربات القلب المهدد للحياة (تورساد&nbsp;دي&nbsp;بوانت) أو توقف ضربات القلب أثناء تناول فياجاسين أقراص (آثار جانبية نادرة جدًا)، <strong>فأخبر طبيبك المعالج على الفور أنك تناولت فياجاسين أقراص ولم تقم بإعادة تناول العلاج.</strong></p><p dir="RTL">وقد لوحظ تفاقم أعراض الوهن العضلي الوبيل في حالات نادرة للغاية. إذا حدث هذا، <strong>استشر طبيبك على الفور</strong>.</p><p dir="RTL">إذا كنت تعاني من مرض السكري ولاحظت أن نسبة السكر في الدم لديك تزيد أو تنقص (من الآثار الجانبية النادرة أو النادرة جدًا)،<strong> أخبر طبيبك على الفور.</strong></p><p dir="RTL">إذا كنت مسنًا وتعاني من مشاكل في الكلى حاليا ولاحظت انخفاضًا في إنتاج البول، وتورم في ساقيك، أو كاحليك أو قدميك، أو تعب، أو غثيان، أو خمول، أو ضيق في التنفس أو الارتباك (قد تكون هذه علامات وأعراضًا لفشل كلوي، من الآثار الجانبية النادرة)، استشر طبيبك على الفور.</p><p dir="RTL">يتم سرد الآثار الجانبية الأخرى التي لوحظت أثناء العلاج بتناول فياجاسين أقراص أدناه من خلال مدى احتمال حدوث الآثار الجانبية:</p><p dir="RTL"><strong>شائع</strong> (قد يؤثر على شخص واحد من كل 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام البطن والمعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقيؤ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الراس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة انزيمات الكبد في الدم (ناقلات الأمين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهابات التي تسببها البكتيريا المقاومة أو الفطريات مثل الالتهابات الفموية والمهبلية التي تسببها المبيضات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيير في إيقاع القلب (ECG) في المرضى الذين يعانون من انخفاض مستوى البوتاسيوم في الدم.</p><p dir="RTL"><strong>غير شائع</strong> (قد يؤثر على ما يصل إلى شخص من كل 100 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في المعدة (عسر الهضم / حرقة في المعدة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغيرات في التذوق (في حالات نادرة جدا فقدان التذوق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل النوم (في الغالب الأرق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إنزيمات الكبد في الدم (غاما - جلوتاميل - ترانسفيز و / أو الفوسفاتيز القلوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء الخاصة (كريات الدم البيضاء، العدلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالحكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بالدوار (الدوران أو السقوط)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كثرة الريح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيير إيقاع القلب (ECG)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف وظائف الكبد (بما في ذلك زيادة انزيم الكبد في الدم (LDH))</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهية وتناول الطعام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام مثل آلام الظهر والحوض والأطراف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة خلايا الدم خاصة اللازمة لتخثر الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة خلايا الدم البيضاء المتخصصة (الحمضات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء (في الغالب ضعف أو تعب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرعشة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الم بالمفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام وسرعة ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس في حالات الربو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إنزيم هضمي في الدم (الأميليز)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأرق / الإثارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بالوخز أو بالتنميل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توسع الأوعية الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتباك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض خلايا الدم الخاصة اللازمة لتخثر الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات البصرية. رؤية مزدوجة وغير واضحة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض معدل تخثر الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الدهون في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم الحمراء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم عضلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة البيليروبين في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجفاف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوهات شديدة بالقلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذبحة الصدرية</p><p dir="RTL">نادر (قد يؤثر على شخص واحد من كل 1000 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتعاش العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هلوسة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم (في اليدين والقدمين والكاحلين والشفتين والفم والحلق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القصور الكلوي (بما في ذلك الزيادة في نتائج اختبارات الخاصة بالكلى مثل اليوريا والكرياتينين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رنين / ضوضاء في الأذنين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان (اصفرار بياض العينين أو الجلد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الإحساس بالجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحلام غير طبيعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تركيز بالانزعاج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في البلع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الرائحة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب التوازن وضعف التنسيق (بسبب الدوخة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان جزئي أو كلي للذاكرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف السمع بما في ذلك الصمم (يمكن عكسه عادة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة حمض اليوريك في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم الاستقرار العاطفي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الكلام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات</p><p dir="RTL">نادر جدًا (قد يؤثر على ما يصل إلى شخص واحد من كل 10000 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيقاعات القلب غير الطبيعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة حساسية الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالانفصال عن النفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة معدل تخثر الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض كبير في خلايا الدم البيضاء (ندرة المحببات)</p><p dir="RTL">علاوة على ذلك؛ كانت هناك حالات نادرة جدًا من الآثار الجانبية التالية التي تم الإبلاغ عنها بعد العلاج بمضادات حيوية أخرى من مجموعة الكينولون، والتي قد تحدث أيضًا أثناء العلاج باستخدام فياجاسين أقراص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الضغط في الجمجمة (تشمل الأعراض الصداع والمشاكل البصرية بما في ذلك عدم وضوح الرؤية، البقع &quot;العمياء&quot; والرؤية المزدوجة وفقدان الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستويات الصوديوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستويات الكالسيوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع خاص من انخفاض عدد خلايا الدم الحمراء (فقر الدم الانحلالي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل بالعضلات مع تلف خلايا العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة حساسية الجلد لأشعة الشمس أو الأشعة فوق البنفسجية.</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p dir="RTL">إذا زادت حدة أي من هذه الأعراض الجانبية، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة، يرجى إبلاغ الطبيب المعالج أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه). بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
  dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span></span><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-1-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الاتصال على المركز الوطني للتيقظ والسلامة الدوائية +966-11-2038222 ، تحويلة: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الهاتف المجاني: 8002490000</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني : npc .drug@sfda .gov .sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www .sfda .gov .sa/npc</p></td></tr></tbody></table><!--[if mso & !supportInlineShapes & supportFields]><span
  dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:453.6pt;
   height:90.7pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span></span><![endif]--><p>&nbsp;</p><p dir="RTL"><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">&nbsp; &nbsp;يرجى الاتصال بالسلطة الصحية المختصة .</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ عند درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي الأطفال أو على مرأى منهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم فياجاسين أقراص بعد انتهاء تاريخ الصلاحية المذكور على العبوة الخارجية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في عبوته الأصلية لحمايته من الرطوبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي أن يتم التخلص من الأدوية في مياه الصرف الصحي أوعن طريق النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. هذه التدابير تساعد في الحفاظ على البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما تحتويه فياجاسين أقراص 400 ملغم</strong></p><p dir="RTL">المادة الفعالة هي موكسيفلوكساسين هيدروكلوريد</p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة على 436.33 ملغم من موكسيفلوكساسين هيدروكلوريد المتوافق مع دستور الأدوية الأوروبي ما يعادل 400 ملغم موكسيفلوكساسين.</p><p dir="RTL"><strong>الصواغات الأخرى هي</strong>: السليلوز دقيق التبلور، كروس كارميلوز الصوديوم، السيليكا الغروية اللامائية، بوفيدون K-30، ستيرات الماغنيسيوم.</p><p dir="RTL"><strong>الصواغات الأخرى لطبقة الكسوة هي</strong>: هيبروميلوز (62.500 ٪)، ثاني أكسيد التيتانيوم (28.730 ٪)، ماكروجول (6.250 ٪)، أكسيد الحديد الأحمر (2.500 ٪)، أكسيد الحديد الأصفر (0.020 ٪).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل فياجاسين أقراص ومحتويات العلبة؟</strong></p><p dir="RTL"><strong>فياجاسين أقراص 400 ملغم</strong></p><p dir="RTL">أقراص على شكل كبسولة محدبة الوجهين ذات اللون الوردي، والأقراص مغلفة بطبقة رقيقة ومدموغة برقم &quot;80&quot; من جانب وحرف &quot;I&quot; على الجانب الآخر.</p><p dir="RTL"><strong>توافر فياجاسين أقراص:</strong></p><p dir="RTL">يتوافر فياجاسين أقراص في عبوات حاوية تحتوي على&nbsp; 1 &times; 5 و 1 &times; 7 شرائط مصنوعة من Alu-Alu</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب حق التسويق:</strong></p><p dir="RTL"><strong>شركة أماروكس السعودية للصناعة </strong></p><p dir="RTL">شارع الجامعة &ndash; الملز &ndash; الرياض 11441</p><p dir="RTL">المملكة العربية السعودية.</p><p dir="RTL">تليفون: + 966 114772215</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ي</strong><strong>صنع في:&nbsp; </strong></p><p dir="RTL">شركة هیترو لاب</p><p dir="RTL">الوحدة &nbsp;V، حیدر اباد ، الهند&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ابريل/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Moxifloxacin Hydrochloride Tablets 400mg 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each Film coated tablet contains Moxifloxacin Hydrochloride equivalent to Moxifloxacin 
400mg.  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pink coloured, capsule shaped, biconvex, film coated tablets debossed with ‘80’ on one side and ‘I’ on the other side. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Moxifloxacin Hydrochloride Tablets 400mg film-coated tablets are indicated for the treatment of the following bacterial infections in patients of 18 years and older caused by bacteria susceptible to Moxifloxacin (see sections 4.4, 4.8 and 5.1). Moxifloxacin should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections or when these have failed:</p><p>-&nbsp;&nbsp; Acute bacterial sinusitis (adequately diagnosed)</p><p>-&nbsp;&nbsp; Acute exacerbations of chronic bronchitis (adequately diagnosed)</p><p>-&nbsp;&nbsp; Community acquired pneumonia, except severe cases</p><p>-&nbsp;&nbsp; Mild to moderate pelvic inflammatory disease (i.e. infections of female upper genital tract, including salpingitis and endometritis), without an associated tubo-ovarian or pelvic abscess. Moxifloxacin Hydrochloride Tablets 400mg film-coated tablets are not recommended for use in monotherapy of mild to moderate pelvic inflammatory disease but should be given in combination with another appropriate antibacterial agent (e.g. acephalosporin) due to increasing Moxifloxacin resistance of <em>Neisseria gonorrhoeae </em>unless Moxifloxacin-resistant <em>Neisseria gonorrhoeae </em>can be excluded (see sections 4.4 and 5.1).</p><p>Moxifloxacin Hydrochloride Tablets 400mg mg film-coated tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous Moxifloxacin for the following indications:</p><p>-&nbsp;&nbsp; Community-acquired pneumonia</p><p>-&nbsp;&nbsp; Complicated skin and skin structure infections</p><p>Moxifloxacin Hydrochloride Tablets 400mg film-coated tablets should not be used to initiate therapy for any type of skin and skin structure infection or in severe community-acquired pneumonia.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology (adults)</p><p>The recommended dose is one 400 mg film-coated tablet once daily.</p><p>Renal/hepatic impairment</p><p>No adjustment of dosage is required in patients with mild to severely impaired renal function or in patients on chronic dialysis i.e. haemodialysis and continuous ambulatory peritoneal dialysis (see section 5.2 for more details).</p><p>There is insufficient data in patients with impaired liver function (see section 4.3). <em>Other special populations </em></p><p>No adjustment of dosage is required in the elderly and in patients with low bodyweight. <em>Paediatric population </em></p><p>Moxifloxacin is contraindicated in children and adolescents (&lt; 18 years). Efficacy and safety of Moxifloxacin in children and adolescents have not been established (see section 4.3).</p><p>Method of administration</p><p>The film-coated tablet should be swallowed whole with sufficient liquid and may be taken independent of meals.</p><p>Duration of administration</p><p>Moxifloxacin 400 mg film-coated tablets should be used for the following treatment durations:</p><p>-&nbsp;&nbsp; Acute exacerbation of chronic bronchitis&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5 - 10 days</p><p>-&nbsp;&nbsp; Community acquired pneumonia&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10 days - Acute bacterial sinusitis&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7 days</p><p>-&nbsp;&nbsp; Mild to moderate pelvic inflammatory disease&nbsp; &nbsp;&nbsp;&nbsp; 14 days</p><p>Moxifloxacin Hydrochloride Tablets 400mg film-coated tablets have been studied in clinical trials for up to 14 days treatment.</p><p>Sequential (intravenous followed by oral) therapy</p><p>In clinical studies with sequential therapy most patients switched from intravenous to oral therapy within 4 days (community-acquired pneumonia) or 6 days (complicated skin and skin structure infections). The recommended total duration of intravenous and oral treatment is 7 -14 days for community-acquired pneumonia and 7 -21 days for complicated skin and skin structure infections</p><p>The recommended dose (400 mg once daily) and duration of therapy for the indication being treated should not be exceeded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to Moxifloxacin, other quinolones or to any of the excipients listed in section 6.1. 
-	Pregnancy and lactation (see section 4.6). 
-	Patients below 18 years of age. 
-	Patients with a history of tendon disease/disorder related to quinolone treatment. 
Both in preclinical investigations and in humans, changes in cardiac electrophysiology have been observed following exposure to Moxifloxacin, in the form of QT prolongation. For reasons of drug safety, Moxifloxacin is therefore contraindicated in patients with: 
-	Congenital or documented acquired QT prolongation 
-	Electrolyte disturbances, particularly in uncorrected hypokalaemia 
-	Clinically relevant bradycardia 
-	Clinically relevant heart failure with reduced left-ventricular ejection fraction 
-	Previous history of symptomatic arrhythmias 
Moxifloxacin should not be used concurrently with other drugs that prolong the QT interval (see also section 4.5). 
Due to limited clinical data, Moxifloxacin is also contraindicated in patients with impaired liver function (Child Pugh C) and in patients with transaminases increase > 5fold ULN. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The benefit of Moxifloxacin treatment especially in infections with a low degree of severity should be balanced with the information contained in the warnings and precautions section.</p><p>Prolongation of QTc interval and potentially QTc-prolongation-related clinical conditions</p><p>Moxifloxacin has been shown to prolong the QTc interval on the electrocardiogram in some patients. In the analysis of ECGs obtained in the clinical trial program, QTc prolongation with Moxifloxacin was 6 msec &plusmn; 26 msec, 1.4% compared to baseline. As women tend to have a longer baseline QTc interval compared with men, they may be more sensitive to QTc-prolonging medications. Elderly patients may also be more susceptible to drug-associated effects on the QT interval.</p><p>Medication that can reduce potassium levels should be used with caution in patients receiving Moxifloxacin (see also sections 4.3 and 4.5).</p><p>Moxifloxacin should be used with caution in patients with ongoing proarrhythmic conditions (especially women and elderly patients), such as acute myocardial ischaemia or QT prolongation as this may lead to an increased risk for ventricular arrhythmias (incl. torsade de pointes) and cardiac arrest (see also section 4.3). The magnitude of QT prolongation may increase with increasing concentrations of the drug. Therefore, the recommended dose should not be exceeded. If signs of cardiac arrhythmia occur during treatment with Moxifloxacin, treatment should be stopped and an ECG should be performed.</p><p>Hypersensitivity/allergic reactions</p><p>Hypersensitivity and allergic reactions have been reported for fluoroquinolones including Moxifloxacin after first administration. Anaphylactic reactions can progress to a life-threatening shock, even after the first administration. In cases of clinical manifestations of severe hypersensitivity reactions Moxifloxacin should be discontinued and suitable treatment (e.g. treatment for shock) initiated.</p><p>Severe liver disorders</p><p>Cases of fulminant hepatitis potentially leading to liver failure (including fatal cases) have been reported with Moxifloxacin (see section 4.8). Patients should be advised to contact their doctor prior to continuing treatment if signs and symptoms of fulminant hepatic disease develop such as rapidly developing asthenia associated with jaundice, dark urine, bleeding tendency or hepatic encephalopathy.</p><p>Liver function tests/investigations should be performed in cases where indications of liver dysfunction occur.</p><p>Serious bullous skin reactions</p><p>Cases of bullous skin reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported with Moxifloxacin (see section 4.8). Patients should be advised to contact their doctor immediately prior to continuing treatment if skin and/or mucosal reactions occur.</p><p>Patients predisposed to seizures</p><p>Quinolones are known to trigger seizures. Use should be with caution in patients with CNS disorders or in the presence of other risk factors which may predispose to seizures or lower the seizure threshold. In case of seizures, treatment with Moxifloxacin should be discontinued and appropriate measures instituted.</p><p>Peripheral neuropathy</p><p>Cases of sensory or sensorimotor polyneuropathy resulting in paraesthesias, hypoaesthesias, dysaesthesias, or weakness have been reported in patients receiving quinolones including Moxifloxacin. Patients under treatment with Moxifloxacin should be advised to inform their doctor prior to continuing treatment if symptoms of neuropathy such as pain, burning, tingling, numbness, or weakness develop in order to prevent the development of an irreversiblecondition (see section 4.8).</p><p>Psychiatric reactions</p><p>Psychiatric reactions may occur even after the first administration of quinolones, including Moxifloxacin. In very rare cases depression or psychotic reactions have progressed to suicidal thoughts and self-injurious behaviour such as suicide attempts (see section 4.8). In the event that the patient develops these reactions, Moxifloxacin should be discontinued and appropriate measures instituted. Caution is recommended if Moxifloxacin is to be used in psychotic patients or in patients with history of psychiatric disease.</p><p>Antibiotic-associated diarrhoea incl. colitis</p><p>Antibiotic-associated diarrhoea (AAD) and antibiotic-associated colitis (AAC), including pseudomembranous colitis and <em>Clostridium difficile</em>-associated diarrhoea, has been reported in association with the use of broad spectrum antibiotics including Moxifloxacin and may range in severity from mild diarrhoea to fatal colitis. Therefore it is important to consider this diagnosis in patients who develop serious diarrhoea during or after the use of Moxifloxacin.</p><p>If AAD or AAC is suspected or confirmed, on going treatment with antibacterial agents, including Moxifloxacin, should be discontinued and adequate therapeutic measures should be initiated immediately. Furthermore, appropriate infection control measures should be undertaken to reduce the risk of transmission. Drugs inhibiting peristalsis are contraindicated in patients who develop serious diarrhoea.</p><p>Patients with myasthenia gravis</p><p>Moxifloxacin should be used with caution in patients with myasthenia gravis because the symptoms can be exacerbated.</p><p>Tendon inflammation, tendon rupture</p><p>Tendon inflammation and rupture (especially Achilles tendon), sometimes bilateral, may occur with quinolone therapy including Moxifloxacin, even within 48 hours of starting treatment and have been reported up to several months after discontinuation of therapy. The risk of tendinitis and tendon rupture is increased in elderly patients and in those treated concurrently with corticosteroids. At the first sign of pain or inflammation, patients should discontinue treatment with Moxifloxacin, rest the affected limb(s) and consult their doctor immediately in order to initiate appropriate treatment (e.g. immobilisation) for the affected tendon. (see sections 4.3 and</p><p>4.8).</p><p>Aortic aneurysm and dissection&nbsp;</p><p>Epidemiologic studies report an increased risk of aortic aneurysm and dissection after intake of fluoroquinolones, particularly in the older population. Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients with positive family history of aneurysm disease, or in patients diagnosed with preexisting aortic aneurysm and/or dissection, or in presence of other risk factors or conditions predisposing for aortic aneurysm and dissection (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet&#39;s disease, hypertension, known atherosclerosis). In case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.</p><p>Patients with renal impairment</p><p>Elderly patients with renal disorders should use Moxifloxacin with caution if they are unable to maintain adequate fluid intake, because dehydration may increase the risk of renal failure.</p><p>Vision disorders</p><p>If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately (see sections 4.7 and 4.8).</p><p>Dysglycemia</p><p>As with all fluoroquinolones, disturbances in blood glucose, including both hypoglycemia and hyperglycemia have been reported with Moxifloxacin. In Moxifloxacin-treated patients, dysglycemia occurred predominantly in elderly diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g. sulfonylurea) or with insulin. Cases of hypoglycaemic coma have been reported In diabetic patients, careful monitoring of blood glucose is recommended (see section 4.8).</p><p>Prevention of photosensitivity reactions</p><p>Quinolones have been shown to cause photosensitivity reactions in patients. However, studies have shown that Moxifloxacin has a lower risk to induce photosensitivity. Nevertheless patients should be advised to avoid exposure to either UV irradiation or extensive and/or strong sunlight during treatment with Moxifloxacin.</p><p>Patients with glucose-6-phosphate dehydrogenase deficiency</p><p>Patients with a family history of, or actual glucose-6-phosphate dehydrogenase deficiency are prone to haemolytic reactions when treated with quinolones. Therefore, Moxifloxacin should be used with caution in these patients.</p><p>Patients with pelvic inflammatory disease</p><p>For patients with complicated pelvic inflammatory disease (e.g. associated with a tubo-ovarian or pelvic abscess), for whom an intravenous treatment is considered necessary, treatment with Moxifloxacin Hydrochloride Tablets 400mg film-coated tablets is not recommended.</p><p>Pelvic inflammatory disease may be caused by fluoroquinolone-resistant <em>Neisseria gonorrhoeae</em>.</p><p>Therefore in such cases empirical Moxifloxacin should be co-administered with another appropriate antibiotic (e.g. a cephalosporin) unless moxifloxacin-resistant <em>Neisseria gonorrhoeae </em>can be excluded. If clinical improvement is not achieved after 3 days of treatment, the therapy should be reconsidered.&nbsp;</p><p>Patients with special cSSSi</p><p>Clinical efficacy of intravenous Moxifloxacin in the treatment of severe burn infections, fasciitis and diabetic foot infections with osteomyelitis has not been established.</p><p>Interference with biological tests</p><p>Moxifloxacin therapy may interfere with the <em>Mycobacterium </em>spp. culture test by suppression of mycobacterial growth causing false negative results in samples taken from patients currently receiving Moxifloxacin.</p><p>Patients with MRSA infections</p><p>Moxifloxacin is not recommended for the treatment of MRSA infections. In case of a suspected or confirmed infection due to MRSA, treatment with an appropriate antibacterial agent should be started (see section 5.1).</p><p>Paediatric population</p><p>Due to adverse effects on the cartilage in juvenile animals (see section 5.3) the use of Moxifloxacin in children and adolescents &lt; 18 years is contraindicated (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interactions with medicinal products<strong> </strong></p><p>An additive effect on QT interval prolongation of Moxifloxacin and other medicinal products that may prolong the QTc interval cannot be excluded. This might lead to an increased risk of ventricular arrhythmias, including torsade de pointes. Therefore, co-administration of Moxifloxacin with any of the following medicinal products is contraindicated (see also section</p><p>4.3):</p><p>-&nbsp;&nbsp; anti-arrhythmics class IA (e.g. quinidine, hydroquinidine, disopyramide)</p><p>-&nbsp;&nbsp; anti-arrhythmics class III (e.g. amiodarone, sotalol, dofetilide, ibutilide)</p><p>-&nbsp;&nbsp; antipsychotics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride)</p><p>-&nbsp;&nbsp; tricyclic antidepressive agents</p><p>-certain antimicrobial agents (saquinavir, sparfloxacin, erythromycin IV, pentamidine,&nbsp;&nbsp;&nbsp;</p><p>antimalarials particularly halofantrine)</p><p>-&nbsp;&nbsp; certain antihistaminics (terfenadine, astemizole, mizolastine)</p><p>-&nbsp;&nbsp; others (cisapride, vincamine IV, bepridil, diphemanil</p><p>Moxifloxacin should be used with caution in patients who are taking medication that can reduce&nbsp;&nbsp; potassium levels (e.g.loop and thiazide-type diuretics, laxatives and enemas [high doses], corticosteroids, amphotericin B) or medication that is associated with clinically significant bradycardia.</p><p>An interval of about 6 hours should be left between administration of agents containing bivalent or trivalent cations(e.g. antacids containing magnesium or aluminium, didanosine tablets, sucralfate and agents containing iron or zinc) and administration of Moxifloxacin.</p><p>Concomitant administration of charcoal with an oral dose of 400 mg Moxifloxacin led to a pronounced prevention of drug absorption and a reduced systemic availability of the drug by more than 80%. Therefore, the concomitant use of these two drugs is not recommended (except for overdose cases, see also section 4.9).</p><p>After repeated dosing in healthy volunteers, Moxifloxacin increased Cmax of digoxin by approximately 30% without affecting AUC or trough levels. No precaution is required for use with digoxin.</p><p>In studies conducted in diabetic volunteers, concomitant administration of oral Moxifloxacin with glibenclamide resulted in a decrease of approximately 21% in the peak plasma concentrations of glibenclamide. The combination of glibenclamide and Moxifloxacin could theoretically result in a mild and transient hyperglycaemia. However, the observed pharmacokinetic changes for glibenclamide did not result in changes of the pharmacodynamic parameters (blood glucose, insulin). Therefore no clinically relevant interaction was observed between Moxifloxacin and glibenclamide.</p><p>Changes in INR</p><p>A large number of cases showing an increase in oral anticoagulant activity have been reported in patients receiving antibacterial agents, especially fluoroquinolones, macrolides, tetracyclines, cotrimoxazole and some cephalosporins. The infectious and inflammatory conditions, age and general status of the patient appear to be risk factors. Under these circumstances, it is difficult to evaluate whether the infection or the treatment caused the INR (international normalised ratio) disorder. A precautionary measure would be to more frequently monitor the INR. If necessary, the oral anticoagulant dosage should be adjusted as appropriate.</p><p>Clinical studies have shown no interactions following concomitant administration of Moxifloxacin with: ranitidine, probenecid, oral contraceptives, calcium supplements, morphine administered parenterally, theophylline, cyclosporine or itraconazole.</p><p><em>In vitro </em>studies with human cytochrome P450 enzymes supported these findings. Considering these results a metabolic interaction via cytochrome P450 enzymes is unlikely.</p><p>Interaction with food</p><p>Moxifloxacin has no clinically relevant interaction with food including dairy products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>The safety of Moxifloxacin in human pregnancy has not been evaluated.. Animal studies have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of immature animals and reversible joint injuries described in children receiving some fluoroquinolones, Moxifloxacin must not be used in pregnant women (see section 4.3).</p><p><u>Breastfeeding</u></p><p>There is no data available in lactating or nursing women. Preclinical data indicate that small amounts of Moxifloxacin are secreted in milk. In the absence of human data and due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of immature animals, breast-feeding is contraindicated during Moxifloxacin therapy (see section 4.3).</p><p><u>Fertility</u></p><p>Animal studies do not indicate impairment of fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of Moxifloxacin on the ability to drive and use machines have been performed. However, fluoroquinolones including Moxifloxacin may result in an impairment of the patient&#39;s ability to drive or operate machinery due to CNS reactions (e.g. dizziness; acute, transient loss of vision, see section 4.8) or acute and short lasting loss of consciousness (syncope, see section 4.8). Patients should be advised to see how they react to Moxifloxacin before driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions based on all clinical trials and derived from post-marketing reports with Moxifloxacin 400 mg (oral and sequential therapy) sorted by frequencies are listed below:<strong> </strong></p><p>Apart from nausea and diarrhoea all adverse reactions were observed at frequencies below 3%. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as: - common (&ge; 1/100 to &lt; 1/10)</p><p>-&nbsp;&nbsp; uncommon (&ge; 1/1,000 to &lt; 1/100)</p><p>-&nbsp;&nbsp; rare (&ge; 1/10,000 to &lt; 1/1,000)</p><p>-&nbsp;&nbsp; very rare (&lt; 1/10,000)</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class </strong></p><p><strong>(MedDRA)</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Common</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Uncommon</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Rare</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Very Rare</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and </strong></p><p><strong>infestations</strong>&nbsp;</p></td><td style="vertical-align:top"><p>Superinfections due to resistant bacteria or fungi e.g. oral and</p><p>vaginal candidiasis</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia</p><p>Leucopenia(s)</p><p>Neutropenia</p><p>Thrombocytopenia</p><p>Thrombocythemia</p><p>Blood eosinophilia Prothrombin time prolonged/INR increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Prothrombin &nbsp; level increased/INR decreased Agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; system</strong></p><p><strong>disorders</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reaction</p><p>(see section 4.4)</p></td><td style="vertical-align:top"><p>Anaphylaxis incl. very rarely lifethreatening shock</p><p>(see section 4.4)</p><p>Allergic oedema / angiooedema (incl. laryngeal oedema, potentially lifethreatening, see</p><p>section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and </strong></p><p><strong>nutrition disorders</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperlipidemia</p></td><td style="vertical-align:top"><p>Hyperglycemia Hyperuricemia</p></td><td style="vertical-align:top"><p>Hypoglycemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anxiety reactions Psychomotor hyperactivity/ agitation</p></td><td style="vertical-align:top"><p>Emotional lability Depression (in very rare &nbsp;&nbsp;&nbsp; cases</p><p>potentially culminating in selfinjurious behaviour, such as suicidal ideations/ thoughts, or suicide attempts, see section 4.4) Hallucination</p></td><td style="vertical-align:top"><p>Depersonalization</p><p>Psychotic reactions</p><p>(potentially culminating in selfinjurious behaviour, such as suicidal ideations/ thoughts, or suicide attempts, see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; system</strong></p><p><strong>disorders</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong>Headache Dizziness</p></td><td style="vertical-align:top"><p>Par- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</p><p>Dysaesthesia</p><p>Taste &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorders</p><p>(incl. ageusia in very rare cases)</p><p>Confusion &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</p><p>disorientation</p><p>Sleep &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorders</p><p>(predominantly insomnia) Tremor</p></td><td style="vertical-align:top"><p>Hypoaesthesia</p><p>Smell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorders</p><p>(incl. anosmia)</p><p>Abnormal dreams Disturbed coordination (incl. gait disturbances, esp. due to dizziness or vertigo)</p><p>Seizures incl. grand mal convulsions (see</p></td><td style="vertical-align:top"><p>Hyperaesthesia</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p><p>Somnolence</p></td><td style="vertical-align:top"><p>section 4.4)</p><p>Disturbed attention</p><p>Speech disorders</p><p>Amnesia Peripheral</p><p>neuropathy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</p><p>polyneuropathy</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual disturbances incl. diplopia and blurred vision</p><p>(especially in the course of CNS reactions, see</p><p>section 4.4)</p></td><td style="vertical-align:top"><p>Photophobia</p></td><td colspan="2" style="vertical-align:top"><p>Transient &nbsp;&nbsp;&nbsp; loss &nbsp;&nbsp;&nbsp; of</p><p>vision (especially in the course of CNS reactions, see</p><p>sections 4.4 and 4.7) Uveitis and bilateral acute &nbsp; iris</p><p>transillumination (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear &nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp; labyrinth</strong></p><p><strong>disorders</strong>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus&nbsp;</p><p>Hearing impairment incl. deafness</p><p>(usually reversible)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>QT prolongation in patients with hypokalaemia (see</p><p>sections 4.3 and</p><p>4.4)</p></td><td style="vertical-align:top"><p>QT &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prolongation</p><p>&nbsp;(see section 4.4) Palpitations</p><p>&nbsp;Tachycardia</p><p>Atrial fibrillation</p><p>Angina pectoris</p></td><td style="vertical-align:top"><p>Ventricular tachyarrhythmias</p><p>Syncope (i.e., acute and &nbsp;&nbsp;&nbsp;&nbsp; short &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lasting loss &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of consciousness)</p></td><td colspan="2" style="vertical-align:top"><p>Unspecified arrhythmias</p><p>Torsade de Pointes (see section 4.4)</p><p>Cardiac arrest (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vasodilatation</p></td><td style="vertical-align:top"><p>Hypertension Hypotension</p></td><td colspan="2" style="vertical-align:top"><p>Vasculitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic</strong></p><p><strong>and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mediastinal </strong></p><p><strong>disorders</strong>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnea (including</p><p>asthmatic conditions)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Nausea</p><p>Vomiting</p><p>Gastrointestinal</p><p>and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal</p><p>pains Diarrhoea</p></td><td style="vertical-align:top"><p>Decreased &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; appetite and food intake Constipation</p><p>&nbsp;Dyspepsia Flatulence</p><p>Gastritis&nbsp;</p><p>Increased amylase</p></td><td style="vertical-align:top"><p>Dysphagia</p><p>Stomatitis Antibiotic associated colitis (incl. pseudo-</p><p>membranous colitis, in very rare cases associated with lifethreatening complications, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; see</p><p>section 4.4)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong>&nbsp;</p></td><td style="vertical-align:top"><p>Increase transaminases</p></td><td style="vertical-align:top"><p>in</p></td><td style="vertical-align:top"><p>Hepatic impairment</p><p>(incl. LDH increase)</p><p>Increased bilirubin</p><p>Increased &nbsp;&nbsp;&nbsp;&nbsp; gamma-</p><p>glutamyl-transferase Increase in blood alkaline phosphatase</p></td><td style="vertical-align:top"><p>Jaundice</p><p>Hepatitis</p><p>(predominantly cholestatic)</p></td><td colspan="2" style="vertical-align:top"><p>Fulminant hepatitis potentially leading to life-threatening liver failure (incl. fatal cases, see</p><p>section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin &nbsp;&nbsp; and subcutaneous &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tissue disorders</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pruritus</p><p>Rash</p><p>Urticaria</p><p>Dry skin</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Bullous skin reactions like</p><p>Stevens-Johnson syndrome or toxic epidermal necrolysis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(potentially</p></td><td style="vertical-align:top"><p>life-</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>threatening, section 4.4)</p></td><td style="vertical-align:top"><p>see</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and</strong></p><p><strong>connective &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tissue </strong></p><p><strong>disorders</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia Myalgia</p></td><td style="vertical-align:top"><p>Tendonitis &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (see</p><p>section 4.4)</p><p>Muscle cramp</p><p>Muscle twitching</p><p>Muscle weakness</p></td><td style="vertical-align:top"><p>Tendon rupture (see</p><p>section 4.4)</p><p>Arthritis</p><p>Muscle rigidity</p><p>Exacerbation</p></td><td style="vertical-align:bottom"><p>of</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>symptoms</p></td><td style="vertical-align:top"><p>of</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>myasthenia</p><p>(see section 4.4)</p></td><td style="vertical-align:top"><p>gravis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary </strong></p><p><strong>disorders</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dehydration</p></td><td style="vertical-align:top"><p>Renal impairment (incl. increase in</p><p>BUN and creatinine) Renal failure (see</p><p>section 4.4)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration </strong></p><p><strong>site conditions</strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Feeling &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unwell</p><p>(predominantly</p><p>asthenia or fatigue) Painful conditions (incl. pain in back, chest, pelvic and extremities) Sweating</p></td><td style="vertical-align:top"><p>Oedema</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>There have been very rare cases of the following side effects reported following treatment with other fluoroquinolones, which might possibly also occur during treatment with Moxifloxacin: hypernatraemia, hypercalcaemia, haemolytic anaemia, rhabdomyolysis, photosensitivity reactions (see section 4.4).<strong> </strong></p><p>Reporting of suspected adverse reactions</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side affects; you can help provide more information on the safety of this medicine.</p><p><strong><em>&bull; </em>Saudi Arabia<em>: </em></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:510px"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><strong>o Other GCC States: </strong></p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific countermeasures after accidental overdose are recommended. In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation. Concomitant administration of charcoal with a dose of 400 mg oral Moxifloxacin will reduce systemic availability of the drug by more than 80%. The use of charcoal early during absorption may be useful to prevent excessive increase in the systemic exposure to Moxifloxacin in cases of oral overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Quinolone antibacterials, fluoroquinolones, ATC code: J01MA14</p><p>&nbsp;</p><p>Mechanism of action</p><p>Moxifloxacin has <em>in vitro </em>activity against a wide range of Gram-positive and Gram-negative pathogens.</p><p>The bactericidal action of Moxifloxacin results from the inhibition of both type II topoisomerases (DNA gyrase and topoisomerase IV) required for bacterial DNA replication, transcription and repair. It appears that the C8-methoxy moiety contributes to enhanced activity and lower selection of resistant mutants of Gram-positive bacteria compared to the C8-H moiety. The presence of the bulky bicycloamine substituent at the C-7 position prevents active efflux, associated with the <em>nor</em>A or <em>pmr</em>A genes seen in certain Gram-positive bacteria.</p><p>Pharmacodynamic investigations have demonstrated that Moxifloxacin exhibits a concentration dependent killing rate. Minimum bactericidal concentrations (MBC) were found to be in the range of the minimum inhibitory concentrations (MIC).</p><p>&nbsp;</p><p>Effect on the intestinal flora in humans</p><p>The following changes in the intestinal flora were seen in volunteers following oral administration of Moxifloxacin:<em>Escherichia coli</em>, <em>Bacillus </em>spp., <em>Enterococcus </em>spp., and <em>Klebsiella </em>spp. were reduced, as were the anaerobes <em>Bacteroides vulgatus</em>, <em>Bifidobacterium </em>spp., <em>Eubacterium </em>spp., and <em>Peptostreptococcus </em>spp.. For <em>Bacteroides fragilis</em> there was an increase.</p><p>These changes returned to normal within two weeks.</p><p>Mechanism of resistance</p><p>Resistance mechanisms that inactivate penicillins, cephalosporins, aminoglycosides, macrolides and tetracyclines do not interfere with the antibacterial activity of Moxifloxacin. Other resistance mechanisms such as permeation barriers (common in <em>Pseudomonas aeruginosa</em>) and efflux mechanisms may also effect susceptibility to Moxifloxacin.</p><p><em>In vitro </em>resistance to Moxifloxacin is acquired through a stepwise process by target site mutations in both type II topoisomerases, DNA gyrase and topoisomerase IV. Moxifloxacin is a poor substrate for active efflux mechanisms in Gram-positive organisms.</p><p>Cross-resistance is observed with other fluoroquinolones. However, as Moxifloxacin inhibits both topoisomerase II and IV with similar activity in some Gram-positive bacteria, such bacteria may be resistant to other quinolones, but susceptible to Moxifloxacin.</p><p>Breakpoints</p><p>EUCAST clinical MIC and disk diffusion breakpoints for Moxifloxacin (01.01.2011):</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Organism</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Susceptible</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Resistant</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus</em> spp.</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 24 mm</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l &lt; 21 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>S. pneumoniae</em>&nbsp;</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 22 mm</p></td><td style="vertical-align:top"><p>&gt; 0.5 mg/l</p><p>&ge; 22 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus</em> Groups A, B, C, G</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 18 mm</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l &lt; 15 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>H. influenzae </em>&nbsp;</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 25 mm</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 25 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>M. catarrhalis</em>&nbsp;</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 23 mm</p></td><td style="vertical-align:top"><p>&gt; 0.5 mg/l</p><p>&lt; 23 mm</p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae</em>&nbsp;</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p><p>&ge; 20 mm</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l &lt; 17 mm</p></td></tr><tr><td style="vertical-align:top"><p>Non-species related breakpoints*</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p></td><td style="vertical-align:top"><p>&gt; 1 mg/l</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* &nbsp;&nbsp;&nbsp; Non-species &nbsp;&nbsp;&nbsp; related &nbsp;&nbsp;&nbsp; breakpoints &nbsp;&nbsp;&nbsp; have &nbsp;&nbsp;&nbsp; been &nbsp;&nbsp;&nbsp; determined &nbsp;&nbsp;&nbsp; mainly &nbsp;&nbsp;&nbsp; on &nbsp;&nbsp;&nbsp; the &nbsp;&nbsp;&nbsp; basis &nbsp;&nbsp;&nbsp;&nbsp; of</p><p>pharmacokinetic/pharmacodynamic data and are independent of MIC distributions of specific species. They are for use only for species that have not been given a species-specific breakpoint and are not for use with species where interpretative criteria remain to be determined.&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Microbiological Susceptibility</p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information of resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought where the local prevalence of resistance is such that utility of the agent in at least some types of infections is questionable.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly susceptible species</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u>&nbsp;</p><p><em>Gardnerella vaginalis</em>&nbsp;</p><p><em>Staphylococcus aureus</em>* (methicillin-susceptible)</p><p><em>Streptococcus agalactiae</em> (Group B)</p><p><em>Streptococcus milleri</em> group* (<em>S. anginosus, S. constellatus and S. intermedius</em>)</p><p><em>Streptococcus pneumoniae</em>*</p><p><em>Streptococcus pyogenes</em>* (Group A)</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><em>Streptococcus viridans </em>group<em> (S. viridans, S. mutans, S. mitis, S. sanguinis, S. salivarius, S. thermophilus)</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u>&nbsp;</p><p><em>Acinetobacter baumanii</em>&nbsp;</p><p><em>Haemophilus influenzae</em>*</p><p><em>Haemophilus parainfluenzae</em>*</p><p><em>Legionella pneumophila</em>&nbsp;</p><p><em>Moraxella (Branhamella) catarrhalis</em>*</p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u>&nbsp; <em>Fusobacterium</em> spp.</p><p><em>Prevotella</em> spp.</p></td></tr><tr><td style="vertical-align:top"><p><u>&ldquo;Other&rdquo; micro-organisms</u>&nbsp;</p><p><em>Chlamydophila (Chlamydia) pneumoniae</em>*</p><p><em>Chlamydia trachomatis*</em>&nbsp;</p><p><em>Coxiella burnetii</em>&nbsp;</p><p><em>Mycoplasma genitalium</em>&nbsp;</p><p><em>Mycoplasma hominis</em>&nbsp;</p><p><em>Mycoplasma pneumoniae</em>*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Species for which acquired resistance may be a problem</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u>&nbsp;</p><p><em>Enterococcus faecalis*</em>&nbsp;</p><p><em>Enterococcus faecium*</em>&nbsp;</p><p><em>Staphylococcus aureus</em> (methicillin-resistant)<sup>+</sup></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u>&nbsp;</p><p><em>Enterobacter cloacae</em>*</p><p><em>Escherichia coli</em>*</p><p><em>Klebsiella pneumoniae</em>*<sup>#</sup></p><p><em>Klebsiella oxytoca </em>&nbsp;</p><p><em>Neisseria gonorrhoeae*</em><sup>+</sup>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Proteus mirabilis</em>*</p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u>&nbsp; <em>Bacteroides fragilis*</em>&nbsp;</p><p><em>Peptostreptococcus</em> spp.*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently resistant organisms</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u>&nbsp;</p><p><em>Pseudomonas aeruginosa</em>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>*Activity has been satisfactorily demonstrated in susceptible strains in clinical studies in the approved clinical indications.</p><p><sup>#</sup>ESBL-producing strains are commonly resistant to fluoroquinolones</p><p><sup>+</sup>Resistance rate &gt; 50% in one or more countries</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption and Bioavailability</p><p>Following oral administration Moxifloxacin is rapidly and almost completely absorbed. The absolute bioavailability amounts to approximately 91%.&nbsp;</p><p>&nbsp;</p><p>Pharmacokinetics are linear in the range of 50 - 800 mg single dose and up to 600 mg once daily dosing over 10 days. Following a 400 mg oral dose peak concentrations of 3.1 mg/l are reached within 0.5 - 4 h post administration.</p><p>Peak and trough plasma concentrations at steady-state (400 mg once daily) were 3.2 and 0.6 mg/l, respectively. At steady-state the exposure within the dosing interval is approximately 30% higher than after the first dose.</p><p>Distribution</p><p>Moxifloxacin is distributed to extravascular spaces rapidly; after a dose of 400 mg an AUC of 35 m∙gh/l is observed. The steady-state volume of distribution (Vss) is approximately 2 l/kg. <em>In vitro </em>and <em>ex vivo </em>experiments showed a protein binding of approximately 40 - 42% independent of the concentration of the drug. Moxifloxacin is mainly bound to serum albumin.</p><p>The following peak concentrations (geometric mean) were observed following administration of a single oral dose of 400 mg Moxifloxacin:</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Tissue</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Concentration</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Site: Plasma ratio</strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Plasma</p></td><td style="vertical-align:top"><p>3.1 mg/l</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Saliva</p></td><td style="vertical-align:top"><p>3.6 mg/l</p></td><td style="vertical-align:top"><p>0.75 - 1.3</p></td></tr><tr><td style="vertical-align:top"><p>Blister fluid</p></td><td style="vertical-align:top"><p>1.6<sup>1</sup> mg/l</p></td><td style="vertical-align:top"><p>1.7<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Bronchial mucosa</p></td><td style="vertical-align:top"><p>5.4 mg/kg</p></td><td style="vertical-align:top"><p>1.7 - 2.1</p></td></tr><tr><td style="vertical-align:top"><p>Alveolar macrophages</p></td><td style="vertical-align:top"><p>56.7 mg/kg</p></td><td style="vertical-align:top"><p>18.6 - 70.0</p></td></tr><tr><td style="vertical-align:top"><p>Epithelial lining fluid</p></td><td style="vertical-align:top"><p>20.7 mg/l</p></td><td style="vertical-align:top"><p>5 - 7</p></td></tr><tr><td style="vertical-align:top"><p>Maxillary sinus</p></td><td style="vertical-align:top"><p>7.5 mg/kg</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p>Ethmoid sinus</p></td><td style="vertical-align:top"><p>8.2 mg/kg</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td style="vertical-align:top"><p>Nasal polyps</p></td><td style="vertical-align:top"><p>9.1 mg/kg</p></td><td style="vertical-align:top"><p>2.6</p></td></tr><tr><td style="vertical-align:top"><p>Interstitial fluid</p></td><td style="vertical-align:top"><p>1.0<sup>2</sup> mg/l</p></td><td style="vertical-align:top"><p>0.8 - 1.4<sup>2,3</sup></p></td></tr><tr><td style="vertical-align:top"><p>Female genital tract*</p></td><td style="vertical-align:top"><p>10.2<sup>4</sup> mg/kg</p></td><td style="vertical-align:top"><p>1.72<sup>4</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>* intravenous administration of a single 400 mg dose</p><p><sup>1&nbsp; </sup>10 h after administration</p><p><sup>2&nbsp; </sup>unbound concentration</p><p><sup>3&nbsp; </sup>from 3 h up to 36 h post dose</p><p><sup>4&nbsp; </sup>at the end of infusion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Biotransformation</p><p>Moxifloxacin undergoes Phase II biotransformation and is excreted via renal and biliary/faecal pathways as unchanged drug as well as in the form of a sulpho-compound (M1) and a glucuronide (M2). M1 and M2 are the only metabolites relevant in humans, both are microbiologically inactive.&nbsp;</p><p>In clinical Phase I and <em>in vitro </em>studies no metabolic pharmacokinetic interactions with other</p><p>drugs undergoing Phase I biotransformation involving cytochrome P450 enzymes were observed. There is no indication of oxidative metabolism.</p><p>Elimination</p><p>&nbsp;</p><p>Moxifloxacin is eliminated from plasma with a mean terminal half life of approximately 12 hours. The mean apparent total body clearance following a 400 mg dose ranges from 179 to 246 ml/min. Renal clearance amounted to about 24 - 53 ml/min suggesting partial tubular reabsorption of the drug from the kidneys.</p><p>After a 400 mg dose, recovery from urine (approximately 19% for unchanged drug, approximately 2.5% for M1, and approximately 14% for M2) and faeces (approximately 25% of unchanged drug, approximately 36% for M1, and no recovery for M2) totalled to approximately 96%.</p><p>Concomitant administration of Moxifloxacin with ranitidine or probenecid did not alter renal clearance of the parent drug.</p><p>Elderly and patients with low body weight</p><p>Higher plasma concentrations are observed in healthy volunteers with low body weight (such as women) and in elderly volunteers. <em>Renal impairment&nbsp; </em></p><p>The pharmacokinetic properties of Moxifloxacin are not significantly different in patients with renal impairment (including creatinine clearance &gt; 20 ml/min/1.73 m<sup>2</sup>). As renal function decreases, concentrations of the M2 metabolite (glucuronide) increase by up to a factor of 2.5</p><p>(with a creatinine clearance of &lt; 30 ml/min/1.73 m2).</p><p>Hepatic impairment</p><p>On the basis of the pharmacokinetic studies carried out so far in patients with liver failure (Child Pugh A, B), it is not possible to determine whether there are any differences compared with healthy volunteers. Impaired liver function was associated with higher exposure to M1 in plasma, whereas exposure to parent drug was comparable to exposure in healthy volunteers. There is insufficient experience in the clinical use of Moxifloxacin in patients with impaired liver function<em> </em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects on the haematopoetic system (slight decreases in the number of erythrocytes and platelets) were seen in rats and monkeys. As with other quinolones, hepatotoxicity (elevated liver enzymes and vacuolar degeneration) was seen in rats, monkeys and dogs. In monkeys CNS toxicity (convulsions) occurred. These effects were seen only after treatment with high doses of Moxifloxacin or after prolonged treatment.</p><p>Moxifloxacin, like other quinolones, was genotoxic in <em>in vitro </em>tests using bacteria or mammalian cells. Since these effects can be explained by an interaction with the gyrase in bacteria and - at higher concentrations - by an interaction with the topoisomerase II in mammalian cells, a threshold concentration for genotoxicity can be assumed. In <em>in vivo</em> tests, no evidence of genotoxicity was found despite the fact that very high Moxifloxacin doses were used. Thus, a sufficient margin of safety to the therapeutic dose in man can be provided. Moxifloxacin was non-carcinogenic in an initiation-promotion study in rats.</p><p>Many quinolones are photoreactive and can induce phototoxic, photomutagenic and photocarcinogenic effects. In contrast, Moxifloxacin was proven to be devoid of phototoxic and photogenotoxic properties when tested in a comprehensive programme of <em>in vitro </em>and <em>in vivo </em>studies. Under the same conditions other quinolones induced effects.</p><p>At high concentrations, Moxifloxacin is an inhibitor of the rapid component of the delayed rectifier potassium current of the heart and may thus cause prolongations of the QT interval. Toxicological studies performed in dogs using oral doses of &ge; 90 mg/kg leading to plasma concentrations &ge; 16 mg/l caused QT prolongations, but no arrhythmias. Only after very high cumulative intravenous administration of more than 50fold the human dose (&gt; 300 mg/kg), leading to plasma concentrations of &ge; 200 mg/l (more than 40fold the therapeutic level), reversible, non-fatal ventricular arrhythmias were seen.</p><p>Quinolones are known to cause lesions in the cartilage of the major diarthrodial joints in immature animals. The lowest oral dose of Moxifloxacin causing joint toxicity in juvenile dogs was four times the maximum recommended therapeutic dose of 400 mg (assuming a 50 kg bodyweight) on a mg/kg basis, with plasma concentrations two to three times higher than those at the maximum therapeutic dose.</p><p>Toxicity tests in rats and monkeys (repeated dosing up to six months) revealed no indication regarding an oculotoxic risk. In dogs, high oral doses (&ge; 60 mg/kg) leading to plasma concentrations &ge; 20 mg/l caused changes in the electroretinogram and in isolated cases an atrophy of the retina.</p><p>&nbsp;Reproductive studies performed in rats, rabbits and monkeys indicate that placental transfer of Moxifloxacin occurs. Studies in rats (p.o. and i.v.) and monkeys (p.o.) did not show evidence of teratogenicity or impairment of fertility following administration of Moxifloxacin. A slightly increased incidence of vertebral and rib malformations was observed in foetuses of rabbits but only at a dose (20 mg/kg i.v.) which was associated with severe maternal toxicity. There was an increase in the incidence of abortions in monkeys and rabbits at human therapeutic plasma concentrations. In rats, decreased foetal weights, an increased prenatal loss, a slightly increased duration of pregnancy and an increased spontaneous activity of some male and female offspring was observed at doses which were 63 times the maximum recommended dose on a mg/kg basis with plasma concentrations in the range of the human therapeutic dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The other ingredients are: Cellulose Microcrystalline, Croscarmellose sodium, Silica colloidal anhydrous, Povidone K-30, Magnesium stearate.</p><p>Film Coating Composition: Hypromellose ( 62.500%), T i t a n i u m Dioxide (28.730%),</p><p>Macrogol(6.250%), Iron oxide Red (2.500%), Iron oxide yellow (0.020%).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store&nbsp;below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;1 X 5&rsquo;s&nbsp; Alu-Alu Blister pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Hetero Lab Ltd. 
Aljameah Street, Malaz quarter,  
Riyadh 11441, Saudi Arabia 
Tel: +966 11 477 2215
Manufacture: 
Hetero Labs Limited Unit-V

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>